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INTRODUCTION
Carcinoma stomach is one of the leading causes of morbidity and mortality accounting 
for 12% of deaths. There has been a decline in its incidence since 1930. Even though the 
incidence of distal gastric  cancer is decreasing  in  western countries,  incidence of proximal 
gastric cancers continue to increase.
 The  overall 5-year  survival  rates  ranging  from  53%   in  Japan  to 10%  in  Eastern 
Europe.A better outcome is obtained in Japan due to an active screening programme resulting 
in  earlier  diagnosis  and  an  aggressive   surgical  approach. The    combination    of 
chemoradiation  therapy  and  curative  resection increases   disease  free  and  overall  survival 
duration    which      has  led  to   recommend  multimodality treatment   in    patient  with 
systemic   disease.  Inspite   of    this  multimodality  treatment  the  morbidity  and  mortality 
continues to be  high.
AIMS OF THE STUDY
This study was mainly to  analyse cases of carcinoma  stomach in our region which 
commonly  present to  the  general  surgeon  in the  department of  general surgery , Tirunelveli 
medical college hospital, Tirunelveli.
The study was conducted in the following principles.
• To study the anatomical location of growth with respect to age and  gender  distribution
• To study the Etiology & Risk factors with respect to anatomical location.
• Study of H.Pylori  association  with  carcinoma  stomach.
• To study the sensitivity and specificity of various investigation modalities used.
• To study the Histopathological variety in relation to the site of growth
• To study the mortality and morbidity rate with reference to treatment modality.
MATERIALS AND METHODS
           This study was conducted in the general surgery department , Tirunelveli  medical 
college  hospital ,Tirunelveli  for  a  period of  30  months,  from June  2006  to  November 
2008.
• 150 Cases of Carcinoma stomach were studied during this period.
• Details of 150 patients with Adenocarcinoma were retrieved and follow up of these 
patients was done with the surgical treatment modalities used and its outcome and 
survival.
• Cancer recurrence after surgery and cancers after GJ for peptic ulcer disease were 
excluded from this study. 
• Age,  gender,  predisposing  factors,  clinical  presentation  and  surgical  treatment 
modalities used were recorded in a prestructured  proforma. 
• The site of the stomach tumours was recognized as involving one of the four sites. 
Namely 
1. OG Junction 2. Proximal Stomach (Cardia & Fundus)
3.  Body    4. Antrum
• Only those cases which received some form of  surgical  treatment were  included  in 
the  study.
• Association of H.Pylori with gastric cancer study was carried out in eleven patients 
of  histologically  proved  gastric  carcinoma.
• The WHO classification of HPE report was combined with Lauren’s HPE  type in 
order  to  study  the  Histopalthology  type in  relation  to  tumour location.
DATA ANALYSIS
• The Commonest abdominal malignancy in our region is CA stomach.
• The Common site of involvement in CA stomach is Pyloric Antrum  constituting  117 
out  of  150  cases.
• This was in concordence with the study of cherian et al (2007), Sivaraman et al.
• This study, is contradictory to the rising incidence of AdenoCA of proximal  growth 
in  the  West,  Iran,  Sweden &  Kerala
SITE DISTRIBUTION
Site No of cases % 1993,TVMCH
OG jn 6 4% 2%
cardia 7 4.6% 2%
Body 15 10% 24%
Antrum 117 78% 48%
Linitisplastica 5 3.3% 10%
• Proximal  growth shows an increase of  2%  when compared  to the  previous  study.
• A  decline in  the incidence  of  body growth (10%) was  found   in  this  study.
• Antral  growth  continues to increase   by   30%   in  this  study.
• The study revealed that the distal  growth  is continue to be increasing  our  region   than 
the    proximal  growth .
AGE   DISTRIBUTION
Site Age   groups<30 30-39 40-49 50-59 >60
OG  jn 2 2 2
Cardia 2 3 2
Body 2 7 2 4
antrum 1 8 16 34 52
Linitisplastica 3 2
• The age group  affected  is evenly distributed   in cancers involving  OG   jn above 40 
years..
• Significant  increase  in  the  number  of patients  after the  age  of 50  years  was  seen 
in  cancers  involving  pyloric  antrum.
• Both the youngest age(24yrs) at presentation and oldest age(84yrs) of presentation were 
seen in Antral growth.
• This  is  concordance  with  the  results  of  Lee  et  al  and  Kim  et al.
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SITE DISTRIBUTION
AGE   DISTRIBUTION
GENDER DISTRIBUTION
Site Male Female Ratio
OG jn 3 3 1
Cardia and fundus 6 1 6
Body 11 4 1.2
Pyloric antrum 96 20 4.6
Linitis plastica 3 2 1.5
• The male : female ratio of cancers involving the proximal stomach, body, antrum and 
OG Jn was 6, 1.2, 4.6 and 1 respectively.
• This was not in  concardance with the study of Cherian et al, where  the ratio is 3, 2, 3 
and 4 respectively.
MEAN AGE  DISTRIBUTION
Site Male Female SJE 2007Male
SJE 2007
Female
OG jn 47.5 47 50.5 46.25
Cardia&fundus 51.4 45 55.47 50
Body 52.5 58.1 55.43 46.37
Antrum 56.7 60.1 55.5 52.86
Linitis plastica 51.3 57.5 - -
• Mean Age of  occurrence  is low  in  both  sexes  having  proximal    growths.
• This  is  in concardance with the study of  Saudi gastroenterology  2007.
ETIOLOGICAL ASSOCIATION
Site Smoking Alchohol
Smoked, 
spicy 
foods
Blood Grouping
A B AB O
Fatty 
food
OG  jn 3 1 2 2 3 0 1 6
Cardia&fundus 3 1 1 3 0 2 1 7
Body 3 2 12 2 3 4 6 5
48
45
18
38
A B AB O
Antrum 62 48 78 39 39 12 27 15
Linitis plastica 3 1 2 2 0 0 3 1
• Smoking contributes 100% association of cancers in OG Jn in males  and 71.4% in 
cardia  and  64.58%  in  Antral  growth.
• Gammon et al,  Inoue et al describes the association between smoking and  proximal 
gastric cancers.
• Blood   group A   is the  most common group  affected by Carcinoma Stomach in our 
region. AIRD describes the association between ca stomach and Blood group A.
• Smoked and spicy food shows an increased association with antral growth.
• Fatty food  has  an  increased  association  with   proximal  cancers.
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H.PYLORI  STUDY
• 11  Patients   underwent  study  of  H.pylori  by  subjecting  them  to  ELISA   of   IgG 
Antibody of   H.Pylori  kit
• About 5ml of blood was drawn from each patient,serum  was  separated  and    the  IgG 
Antibodies  were  measured.
• The results  were interpreted  as positive if the value is above 20IU  and  negative  if  it 
is  below  20IU.
• One  patient with OG jn  growth ,two patients with body of growth, eight  patients with 
pyloric antral growth  were subjected to study.
• The study includes  seven patients  of more than 60 years  of age, two  patients  of   fifty 
to  sixty  years  of  age, one  patient  below 50  years  of  age  and  one  patient  of  thirty 
five  years  of  age.
• Of  these six patients are with  blood group A,  eight  patients with intestinal type  of 
lauren’s  classification, one patient with mucinous Adenocarcinoma and two patients 
with  poorly differentiated  Adenocarcinoma.
           From  this  study ,the  following  results  were  obtained
• H. Pylori showed  an association  with   intestinal  type  of   86.5%
• This  is   in   concordance  with  study  of   Anderson et al  of 90% 
• Age  group  affected  in  H.pylori infection   is  above  60 yrs.
• This  study  corelates  well   with study   of Feilding  et al &  Hunt et  al, shows an 
association  of age group affected above  60 yrs.
• H. Pylori  shows an  association with antral growth in 27.2% of patients and body of  the 
stomach  in  18%  of   patients
• Sibata  et  al shows an association of 68% with antral growth  50%  with  cardia  growth 
and  66%  with  body  of  growth.
• H.Pylori  shows an   50%  Association   with   BLOOD  Group A.
SENSITIVITY & SPECIFICITY OF INVESTIGATIONS
Site Endoscopy USG BA meal Ba swallow
OG jn 96% 0% - 42.8%
Cardia&fundus 100% 0% -
Body 100% 20% - -
antrum 96.39% 90% - -
Linitis plastica 20% 40% 100% -
• Endoscopy  was  done  for  140 cases
• Endoscopy and Biopsy shows 96.39% in detecting Antral growth  and  100%  in 
detecting  Cardia &  Body  growth  and 96%  in  detecting  growth  in  OG Jn.
• USG has a sensitivity in detecting  Antral growth as Antral wall  thickening in  90% 
of  cases.
• Ba meal has a sensitivity of 100% in detecting Linitis   Plastica.
HISTOPATHOLOGY ASSOCIATION
Site Intestinal type
Diffuse 
type Mixed
Chandha, khan et al
2007
Intestinal 
type
Diffuse 
type
Mixed 
type
OG jn 2( 33.3%) 4(66.6%) - - - -
Cardia & 
fundus
2(28.5) 3(66.6%) 2 5.3% 15.3% -
Body 11(73.3%) 4(2.6%) - 8% 15.3% 4%
Antrum 107 
(91.45%)
7(5.9%) 3 28% 27.3% 8%
Linitis plastica - 5(100%) - - - -
96%
100%
100%
96.39%
20%
OG jn Cardia&fundus Body antrum Linitis plastica
• The Intestinal type of Lauren’s classification is found in 91.45% of cases of Antral Growth.
• The diffuse type contributes to 5.9%    in  growth  of     Antral cancers.
• The mixed type  contributes  1%  in  Antral  growth.
• The diffuse type is predominantly seen in proximal cancers and Linitis Plastica contributing 
66.6%.
ENDOSCOPY AND  BIOPSY
INTESTINAL TYPE
28.5
73.30% 83.76% 0 33.30%
OG jn Cardia & fundus Body Antrum Linitis plastica
Chandha et al and  khan et al  in 2007  describes   intestinal type is more common in the 
pyloric antrum and  cardia and fundus growth shows a predominance of  diffuse  type.
STAGING
Stage No of patients %
Stage 1a - -
Stage 1b - -
Stage 2 10 6.6%
Stage3a 11 7.3%
Stage3b 3 2%
Stage 4 126 84%
Site Stage1a
Stage
1b Stage2 Stage3a Stage3b Stage4
OGjn 1 5(83.3%)
Cardia 1 1 5
Body 2 1 1 11
Antrum 6 9 2 100(66.6%
)
Linitis 5(100%)
• The proximal tumours are usually advanced at presentation and  have poorer long term 
prognosis  -anderson et al
• In  this  study  OG  jn  growth   shows   of  83.3%  STAGE  4  disease
&pyloric antrum shows 66.6% of   STAGE 4 disease
NODAL STAGING
Staging No of patients %
No 28 18.6%
N1 94 62.6%
N2 20 13.3%
N3 1 0.6%
M STAGING
Staging No of patients %
M0 24 16%
M1 16 10.6%
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SURGICAL RESULTS
Surgery No of cases Morbidity Mortality
Anderson et 
al Mortality
Total gastrectomy 8 12.5% 37.5% 8%
Sub total gastrectomy 8 - - 10%
Distal gastrectomy 10 - -
Distal gastrectomy and
Roux en y
3 - - -
Palliative    distal 
gastrectomy
44 - 2.8% 7%
Anteriorgastrojejunostomy 63 1.3% 9.5% -
Feeding jejunostomy 14 - 2.8% -
• Total gastrectomy was done for eight patients with a morbidity rate in  two  cases 
and  mortality  of  three cases.
• The palliative procedure shows high morbidity may be due to  disease  process  in 
my   study.
• Anastomotic  leak  was  found  in  six   patients  with   4%.
• .The most devastating complication is anastomatic leak in 3%-21% of cases - 
anderson et al
• Death  due  to  co  morbid illness  in  4%  of  patients.
• Sub total gastrectomy and curative  distal gastrectomy did not show any mortality in 
my study.
REVIEW OF LITERATURE
Carcinoma stomach is the one of the leading cause of cancer related death in world 
wide. It is the  eighth most common cancer in US. It is the seventh  most common cancer In 
India.  There has been decline in its incidence since 1930. Although the incidence of distal 
gastric cancer is decreasing in the world, the incidence of proximal gastric tumors continues to 
increase.
The approximate incidence of gastric carcinoma in the United States is 10cases/1,00,000 
people. In Japan -78 Cases/1,00,000 people. In India, cancer stomach is the 6th common cancer 
in male and 7th most common cancer in female.In TVMCH the incidence of ca stomach is 
8.79% based on cancer registry  during the period 2001-2002. In particular, gastric cardiac 
tumors are five times more common and non-cardia gastric tumors are twice as common in 
men  as  women.  The  incidence  is  also  higher  in  low  socio  economic  populations  of 
developing countries. Survival rates in patients with gastric cancer is poor. The overall 5-year 
survival rates ranging from 53%  in  Japan  to 10% in Eastern Europe. The analysis of the 
national cancer Data base of US revealed 6% to 12% better 5 year survival rate for women 
than for  men, for patients with distal  as opposed to proximal tumours.  continues to be high.
HISTORY
 Billroth, Wölfler 1881    First  successful resection on human patient
Wölfler,nicolondi 1881    Performed antecolic gastrojejunostomy 
Braun 1893    Described jejunojejunostomy as routine 
                                               addition  to gastrojejunostomy
 Billroth,          1874    Billroth I - Distal gastric resection with
                                               anastomosis of Stomach and  duodenum. Billroth II - 
Anastomosis of stomach with  jejunum 
                                                through    transverse mesocolon
ANATOMY  OF STOMACH.
For descriptive purposes ,the stomach is divided into
Lesser curvature
This continue  with  the  right  free border esophagus and forms the  concave border of 
the stomach.
Greater curvature
This starts at the cardiac notch  and forms the convex  border of the  stomach.
The fundus
This is the area above the horizontal line from the cardiac  notch to the greater curvature 
of the stomach.
The incisura angularis
In a J shaped stomach this is the junction of vertical and  horizontal  parts of the lesser 
curvature
The body
This is the portion of stomach  lying  between   the fundus and  pyloric portion of 
stomach.
The pyloric portion
The distal one fifth of the stomach consists of pyloric antrum ,canal and  sphincter .The 
pyloro duodenal junction is identified by the vein  of mayo.
SURGICAL ANATOMY OF STOMACH 
SKANDALAKIS ET AL  divide the stomach into proximal gastric unit 
and distal gastric unit.
Proximal gastric unit consists of
Distal esophagus   -  0.5 -2.5cm
Og jn and esophageal hiatus
ANATOMY OF STOMACH
                         BLOOD   SUPPLY OF STOMACH
Proximal stomach(cardia &fundus)
Distal gastric unit consists of
Gastric antrum
Pylorus 
1st  part  of  duodenum  -first  2.5  cm of  duodenum 
Relations of  proximal  gastric  unit 
Lesser & greater curvature
The upper part of lesser sac
OG  jn
Lesser curvature of body, GE jn  and  the  abdominal  esophagus  are attached to the hepato 
gastric ligament and  its  contents .The greater curvature attaches to the upper part of greater 
omentum and several related  splenic  ligaments.like  gastrosplenic and splenoleinal  ligament. 
Relations of distal gastric unit
The lesser curvature of  antrum, pylorus and  upper part of duodenum are attached to 
hepatogastric  and  hepato duodenal  ligament
The greater curvature is attached to gastrocolic ligament.
Posterior relations  of  distal gastric unit
• Floor of lesser sac
• Transverse mesocolon
• head  &  neck of pancreas
• Aorta&celiac trunk & branches
• Celiac ganglion & plexus
• Hepatic triad
• Gastro duodenal artery
Anterior relations  of distal gastric  unit
• Anterior abdominal  wall
• Medial  segment  of  left  lobe  and  anterior  segment  of  right lobe  of liver
• Transverse mesocolon
• Neck of gall bladder
BLOOD SUPPLY OF STOMACH
The four main arteries of stomach are
LEFT GASTRIC ARTERY
Arises from coeliac axis The left gastric artery commonly divides into an anterior and a 
posterior branch before attaining the lesser curvature111 and, in such cases, the esophageal and 
cardioesophageal arteries may arise, variably, from either of those vessels; more commonly, 
however, the cardioesophageal artery arises from the anterior gastric branch. 
After its cardioesophageal branch the left gastric artery usually curves downward to the 
right and thereafter descends along the lesser curvature. As it descends, it bifurcates into an 
anterior branch which sends branches to the anterior gastric wall, and a posterior branch which, 
similarly, supplies the posterior gastric wall. A smaller continuation of the left gastric artery 
continued along the lesser curvature.
RIGHT  GASTRIC  ARTERY
The right gastric artery  is a small branch which arises most commonly from the proper 
hepatic artery (50-68%), left hepatic artery (28.8-40.5%), common hepatic (3.2%), The right 
gastric  artery  gives  origin  to  one  or  more  suprapyloric  branches.  Anterior  and  posterior 
branches from these anastomose with infrapyloric vessels and with the supraduodenal artery, 
providing for the distal gastric unit (antrum, pyloric canal, first inch (2.54 cm) of the first part 
of the duodenum). The right gastric passes along the lesser curvature for about 4 to 6 cm, about 
0.5 cm from the lesser curvature, before anastomosing with the left gastric. In about 13% of 
individuals, the right gastric artery provides origin for the supraduodenal artery.
RIGHT  GASTRO EPIPLOIC ARTERY
The  right  gastroepiploic  artery   is  a  branch  of  the  gastroduodenal  artery  (or  its 
continuation) in most cases. It occasionally arises from the superior mesenteric artery or from 
the anterior superior pancreaticoduodenal artery. After giving origin to an infrapyloric branch, 
the  artery  passes  along  the  greater  curvature  of  the  distal  gastric  surgical  unit  within  the 
gastrocolic ligament. It gives origin to 8-18 singular or paired anterior and posterior branches 
for  the  gastric  wall.  The  gastric  branches  of  the  right  gastroepiploic  artery  pass  mostly 
undivided in a submucosal position about one-fifth of the distance from the greater curvature. 
They  anastomose  extensively  with  branches  from  the  left  gastric  artery.108 If  the  first 
infrapyloric branch is particularly large, the first following gastric branch tends to take its origin 
further around the greater curvature. In about 75% of individuals, the right gastroepiploic artery 
clearly anastomoses with the left gastroepiploic,111 although not so profusely as is seen in the 
anastomoses with the left gastric artery. 
The gastroduodenal artery ran in front of the common bile duct and descended along the 
posterior surface of the head of the pancreas 
LEFT GASTRO EPIPLOIC ARTERY
The left gastroepiploic artery is the largest branch of the splenic artery.56 It reaches the 
stomach at a point about halfway along the greater curvature,  after it  has already delivered 
several rather long branches to the more proximal part of the greater curvature. These branches 
reach the stomach by way of the gastrosplenic ligament.The left gastroepiploic artery gives off 
the  left  epiploic  and  the  anterior  epiploics.  Together  with  similar  branches  of  the  right 
gastroepiploic, they form the arc of Barkow , which is reinforced also by the posterior epiploic 
branches of the inferior pancreatic artery . 
VEINS OF THE STOMACH:
The veins of the stomach  mainly accompany the arteries. Of particular importance  is 
the left gastric or coronary vein,receives branches  from the esophagus.
LYMPHATIC SUPPLY OF STOMACH
The lymph nodes concerned in the drainage of stomach are.
HEPATIC GROUP
 Lymph nodes lie in the lesser omentum along the bile ducts  and receive lymph from 
the liver and gall bladder.
SUB PYLORIC GROUP
Lie in  the  angle  between  first  and  2nd   parts  of  duodenum on the head of pancreas 
in relation to duodenal artery.Receive the lymph from right  two  thirds  of  greater  curvature 
of  stomach.
GASTRIC GROUP
Superior nodes    - lie  along  left  gastric  artery  and  para  cardial nodes
Inferior  nodes     - lie  along  the  pyloric  half  of  greater  curvature  of 
 the  stomach
PANCREATICOLIENAL GROUP
These  lie  along  the  splenic artery in relation to upper border of pancreas.
JAPANESE CLASSIFICATION OF LYMPH NODES
1. Rt. Paracardial
2. Lt Paracardial
3. Along Lesser Curve
4. Along Greater Curve
5. Suprapyloric
6. Subpyloric
7. Lt Gastric
8. Common HepaticCoeliac Axis
9.  Splenic Hilum
10.  Splenic Artery
11.  Hepatoduodenal Ligament
12.  Retropancreatic
13.  Superior mesentric
LYMPHATIC SUPPLY OF STOMACH
JAPANESE CLASSIFICATION OF  LYMPHATIC SUPPLY OF STOMACH
14.  Middle colic
15.  Para aortic
16. Anterior pancreatic
17.  Inferior pancreatic
18.  Infra diaphragmatic
19.  Oesophagial Hiatus
20.  Lower Paraoesophageal
21.  Supra diaphragmatic
The gastric wall consists of the serosa, the muscular layer, the submucosal layer, and the 
mucosal layer. 
SEROSAL LAYER
The serosa is nothing more than the peritoneum, a thin layer of loose connective tissue 
underlying a layer of simple squamous mesothelium.
MUSCULAR LAYER 
The  anatomist  describes  the  three  well-known  layers  of  musculature:  an  outer 
longitudinal  layer,  middle  circular  layer,  and  inner  oblique  The  outer  longitudinal  layer  of 
muscle is present along the lesser and greater curvatures Its fibers are arranged into two groups. 
The first set is continuous with the outer smooth muscle layer of the esophagus. The fibers are 
best developed along the curvatures,  ending proximal to the pyloric region. The second set 
begins in the body and passes to the right, with the fibers becoming thicker as they near the 
pylorus. 
The  middle  circular  layer  rather  uniformly  encircles  the  entire  stomach  and  "is  the 
principal part of the muscular coat," according to Woodburne.55 This layer becomes thicker at 
the pylorus, most distally forming the pyloric sphincter .
The inner oblique muscle layer, internal to the circular layer, is limited to the body of the 
stomach and is most developed near the cardiac orifice.
SUBMUCOSAL LAYER
The  submucosa  is  composed of  loose,  areolar  connective  tissue  which  connects  the 
mucosa to the external  musculature.  It  can be called the "vascular layer" (both arterial  and 
venous) of the gastric wall. It houses plexuses that have rich anastomoses through extensive 
ramifications that form excellent collateral flow. All the parts of the gastric mucosa receive 
blood from th ese   submucosal plexuses except the lesser curvature.
 MUCOSAL LAYER
• The distal esophagus is lined by stratified squamous epithelium, with mucous cells in the 
abdominal esophagus
• The cardia contains simple columnar cells
GASTRIC MUCOSA SURFACE
• The fundus and body contain two types of cells: parietal (oxyntic) acid-secreting cells 
and chief pepsin-secreting cells
• The lamina propria of the fundus and body is filled with branched, tubular gastric glands
RISK FACTOR 
HELICOBACTER . PYLORI
Sibata et al & Huang et al found H.Pylori positivity is more associated with non-cardia 
gastric  cancer. H.plyori  was  detected  in 90% of  intestinal type of cancer &32% of diffuse 
type  cancer. It is also as associated with  MALT and gastric Lymphoma. H.Pylori increases the 
risk of gastric cancer  by impairing the  bioavailability of vitamin C.
WARREN, in 1980  detected a curved s shaped bacilli in light microscopy. Initially it 
was  recognized  as  campylobacter  jejuni.in  October  1989,  the  organisms  was  named 
helicobacter, because of the presence of sheathed flegelle,a unique fatty acid profile, different 
repiratory quionones.The isolation of H.Pylori from the gastric mucosa and the report of the 
organisms urease activity  was postulated by MARSHALL.
H. Pylori is almost  associated with  inflammatory response.The spiral shaped organisms 
allows efficient motility in the mucus and in the gastric juice. The enzyme urease by breaking 
down  urea in the gastric juice  appears to generate enough bicarbonate and ammonium  ions 
around the organisms to allow its safe passage  through the  gastric acid barrier  to reach the 
mucous layer.Ammonia  elevates the pH of the gastric mucosa  from about  6-7.It is known to 
deplete  aerobic cells of  alpha keto glutarate, an essential substrate  for the TCA   acid cycle. 
Once attached to the mucus layer and the mucosa, H.Pylori,  secretes soluble proteases and 
phospolipase, which may be harmful to the mucus layer.
The vacuolating cytotoxin is a 87  kda  protein  , expressed in about   65%  of  H.Pylori 
strains and is responsible for creating vacuoles   in the epithelial cells. The gene for cytotoxin 
protein is  V ac A. The  Vac  gene is present in all H.Pylori bacteria but only produces an 
active protein in 65% of isolates.A second protein at 127 kda is called  cytotoxin associated 
gene and is called Cag  A   gene. Cag  A   gene is a marker   for vacuolating  cytotoxin effect 
and is only present  when Vac A cytotoxin is present. The organisms have been classified into 
Type І  0rganisms which have  Cag  A  and Vac A which are more ulcerogenic and type ІІ 
organisms that lack Cag A and do not produce cytotoxins.  H. Pylori infection is associated 
with  increase gastrin levels and decrease somatostatin levels, which has led to the development 
of atrophic gastritis  ,a precancerous condition of  gastric carcinoma.  Epidemiological studies 
have  demonstrate  that  there  is   an  association  of   H.Pylori  with  gastric  carcinoma  .  this 
infection has three fold to six fold higher risk for developing  gastric cancer than those without 
infection.                  
The incidence of gastric carcinoma  tends to be high in geographic regions  were  people 
consumes  diets  high  in  salt & smoked  foods. The presence of nitrosamines  in the smoked 
food is a carcinogen in developing the carcinoma.
Smoking has a five-fold increased risk of   cardia and upper-third gastric cancer and   a 
two-fold     increased  risk  of  distal  gastric  cancer  compared to   nonusers.
Male  gender,  Black  race  &  low  socio  economic  class  are  associated  with  Gastric 
carcinoma.
                Obesity is  associated with Proximal gastric cancer.
                Occupational hazard exists for metal workers is a associated factor for distal gastric 
cancer.. 
               An associate  between  gastric carcinoma and  blood   group  A was  described  in 
1953  by…AIRD ET AL….
PREDISPOSING FACTORS
Gastric  polyps particularly  Villous   Adenomas   indicate   increased   risk   of 
malignancy.
Pernicious Anemia is  associated  with  10%  incidence  of  gastric cancer. 
 Mutations  in  CDH1…. Gene  that  encodes  E. Cadherin   is more  common  in 
diffuse   type   gastric   cancer.  Mutations  in  the  CDH1 gene  that  encodes  E-cadherin,  an 
epithelial cell adhesion molecule, may be found in intestinal cancers but are more common in 
diffuse-type gastric cancers. Furthermore, defects in E-cadherin  mediated cell adhesion are 
characteristic of diffuse-type gastric tumors. It also appears that a CDH1 gene mutation occurs 
in  a  cluster  of  patients  with  hereditary  diffuse  gastric  cancer.  Therefore,  prophylactic 
gastrectomy is offered to carriers of these mutations. Virtually all carriers of this mutation so 
far have been found to harbor an early malignancy in the resected specimen, despite negative 
initial endoscopy findings, pointing to the advisability of the gastrectomy.
Vascular endothelial growth factor C (VEGF-C) is a glycoprotein that belongs to the 
VEGF family. VEGFs are cytokines that play an important role in angiogenesis.    In gastric 
adenocarcinomas, expression of VEGF-C mRNA is associated with lymphatic invasion, lymph 
node metastasis, and possibly a less favorable outcome
P53  over  expression revealed  in  more  than  55% of tumors.
Previous  partial gastrectomy  &  Menetrier’s disease –  Pre disposing  factor for  gastric 
cancer.
Hypogammaglobulinaemia  is  associated  with   gastric  cancer.
PATHOLOGY
Approximately   10% of these  tumours    are polypoid fungating  tumours, with  a 
relatively    good    prognosis   after  aggressive  surgical   management. Ulcerating  or 
penetrating cancers,  which   occur in more than  50% 0f patients, are sessile.  Superficial 
spreading carcinoma  is more unusual( 6% of tumours). This tumour is diffusely  infiltrative 
over a wide area,although it is predominantly  confined to mucosa  and submucosa. A further 
subgroup  of   diffusely   infiltrative   cancer   is  the  LINITIS   PLASTICA (leather  bottle) 
carcinoma  and carries particularly  poor prognosis.
EARLY GASTRIC CANCER
           The  term  early gastric cancer describes   tumours  confined  to the   gastric mucosa 
and  submucosa, irrespective  of  nodal  status. Based on endoscopic appearance,( JAPANESE 
CLASSIFICATION),it is divided into three groups,type-1 protruding ,type -2 superficial ,and 
type-3  –  excavated.  Type  -2  is  divided  into   three  subgroups,a)  elevated   b)  flat  and 
c)depressed Early gastric cancer accounts  for 40%  of  all gastric cancers in Japan.  In the 
west,early gastric cancer accounts for 9% of all  cancers detected.50% of cases  progress to 
advanced  cancer within three years from the time of endoscopic  diagnosis, and almost all 
patients develop  advanced disease within five years.
CA STOMACH WITH ASCITES
   METASTATIC CUTANEOUS  NODULES IN  CA STOMACH 
ADVANCED GASTRIC CANCER
Advanced  gastric  cancer  suggests  invasion of  the  muscularis  mucosa or  beyond.  It 
shows  serosal  involvement,  invasion  of  adjacent  organs,extensive  nodal  metastasis  and 
secondary deposits usually within the peritoneal cavity.By, definition these tumours always 
exceed two cm in diameter    (.BORRMANS CLASSIFICATION)
MICROSCOPIC APPEARANCE
The great majority of gastric cancers are Adenocarcinoma; other tumours are rare.
WHO CLASSIFICATION
The   WHO  classification based on morphology  divides gastric cancers  are  into five 
types:adeno carcinoma,adenosquamous carcinoma, squamous cell carcinoma, undifferentiated 
carcinoma, and unclassified carcinoma.   Adenocarcinomas contribute 95% of gastric cancers 
which arises from the mucous producing rather than acid producing cells of gastric mucosa 
The adeno carcinoma  are divided into  four patterns; papillary, tubular, mucinous, and  signet 
ring, which  may be divided by  degrees of differentiation. In tumours presenting a mixed 
picture  with  varying  degrees   of  differentiation  in  the  same  tumour  ,is  based  on  the 
predominant type.
Lymphomas , carcinoid, Leiomyosarcoma,  GIST  of stomach , adenosquanmous and 
squamous cell carcinoma comprise 5% of gastric cancers. 
LAUREN’S CLASSIFICATION:
According to Lauren’s classification, the two  Histologic  types of gastric carcinoma are 
intestinal and diffuse. The intertinal type have the tendency of Malignant cells to form glands. 
The diffuse type lacks organized gland formation, ie usually poorly differentiated and has many 
signet ring cells.The  intestinal  type  carries  the the more favorable prognosis and  is  more 
common in areas with a high incidence  of  the  disease.
MING CLASSIFICATION
    In this classification ,cancers were divided into  an  expanding  type that  produces  nodules 
that compress  adjacent  tissue (Laurens intetinal type), and the infiltrative  type  that does not 
forms masses( Lauren’s diffuse type)
CLINICAL PRESENTATION
Gastric adenocarcinoma is usually not associated with specific symptoms early in the 
course of the disease. Patients often ignore the vague epigastric discomfort and indigestion that 
portend the cancer and may be treated presumptively for benign disease for 6 to 12 months 
before diagnostic studies are performed. Rapid weight loss, anorexia, and vomiting are usually 
a sign of advanced disease.  These presenting features are simply due to the presence of a 
partially obstructing lesion .
            The epigastric pain is usually similar to the pain caused by benign ulcers and is often 
relieved by eating food; however, it can mimic angina. Dysphagia is usually associated with 
tumors  of  the  cardia  or  gastroesophageal  junction.  Antral  tumors  may cause  symptoms of 
gastric outlet obstruction. Although very rare, large tumors that directly invade the transverse 
colon may present with colonic obstruction. Physical examination will reveal a palpable mass 
in up to 30% of patients.
          
Signs of Metastasis disease is found in 10% of patients.
The most common indications of distant metastasis are a palpable supraclavicular  lymph 
node  (Virchow  node),  a  mass  palpable  on  rectal  examination  (Blumer  shelf),  a  palpable 
periumbilical  mass (Sister Mary Joseph node),  ascites,  jaundice,  or a  liver mass.  The most 
common site of hematogenous spread is the liver; tumor also frequently spreads directly  to the 
lining of the peritoneal cavity
 Gastric  tumors  may  be  associated  with  chronic  blood  loss,  but  massive  upper 
gastrointestinal bleeding is rare. In Japan, the high incidence of gastric cancer has led to routine 
endoscopic  screening;  as  a  result,  in  that  country,  more  than  50% of  gastric  cancers  are 
diagnosed at an early stage.
STAGING SYSTEM
           The  Pathologic  staging  system  currently  in  use   worldwide  is  the  American  joint 
committee  on  cancer  TNM  staging  system  with  the  addition of the term R status to denote 
residual  disease  remaining  after  resection
TNM STAGING
The   American  joint  committee  on cancer (AJCC)  has  designated staging by TNM 
classification.
PRIMARY TUMOUR
• Tx  : Primary tumour cannot be assessed
• T0:  no evidence of primary tumour
• Tis: carcinoma in situ: intra epithelial tumour without invasion of the lamina propria
• T1:Tumour invades lamina propria or submucosa
• T2:Tumour invades the muscularis propria or the submucosa
1. T2a:Tumour invades muscularis propria
2. T2b:Tumour invades subserosa
• T3:  Tumour  penetrates  the  serosa(visceral  peritoneum)  without  invading  adjacent 
structures
• T4: Tumour invades adjacent structures.
REGIONAL LYMPH NODES
• Nx:  Regional   lymph nodes cannot  be assessed
• N0:  No regional lymph node metastasis
• N1:Metastasis in   1-6 regional lymph  nodes
• N2:Metastasis in  7-15 regional lymph nodes
• N3:Metastasis in  more than 15  regional  lymph  nodes.
DISTANT METASTASIS
• Mx:Distant metastasis cannot be assessed
• M0:No  distant metastasis
• M1:Distant metastasis.
AJCC STAGING
Stage  0      (Tis,N0,M0)
Stage 1a     (T1, NO,MO)
Stage1b      (T1,NI,MO;T2A,N0,M0;T2B,NO,MO)
StageІ І      (T 1,N2,MO;T2A,NI,MO;T2B,N1,M;T3,NO,MO)
StageІІІА  (T2A,N2,MO;T2B,N2,MO;T3,NI,MO;T4,NO,MO)
StageІІІВ  (T3,N2,MO)
StageІV    (T4,N1,MO;  T4,N2,M0; T4,N3,MO; T1,N3,MO;T2,N3,M0;   T3,N3,M0;    Any 
T,ANY  N,M1)  
RESIDUAL DISEASE
R status described by Hermanek and wittekind in 1994 is commonly used to describe the 
tumour status in a patient following resection and is designated following pathologic evaluation 
of resection margins.
R0 -   No residual gross disease and Negative microscopic
               margins.
R1 -    Microscopic residual disease only
          R2        -   Gross residual disease.
INVESTIGATIONS
UPPER  GI  ENDOSCOPY:
Differentiation between benign & malignant gastric  ulcers at endoscopy can be difficult 
and  several  biopsies  are  taken  (ideally  six)  from  all  parts  of  ulcer.  Diagnostic  accuracy 
approaches 100% if 10 samples are taken.
BARIUM MEAL
It gives a better impression of anatomy of tumour, and the degree of obstruction. It is 
also helpful for diagnosis of linitis plastica which may be missed at gastroscopy.
CT SCAN
           
Abdominal and  pelvic CT is performed in the  overall  staging  of patients. CT chest 
may be required for complete staging of proximal gastric tumours. The major limitations of CT 
as  a  staging  tool are in the evaluation of early  gastric tumors and  small  metastases  in  the 
Liver. The  overall   accuracy in determining  tumors  stage  is  66%  to 77%. CT can be used to 
determine nodal stage in 25% to 86% of patients.
ENDO ULTRASOUND
The overall staging accuracy of EUS is 75%. It correctly identifies T2 leisons (38.5%) 
of the time. It is better at identifying T1(80%) and T3(90%) lesions. The accuracy of EUS in 
the nodal evaluation is 65%.
LAPAROSCOPY
          
The Clinical benefit of laparoscopic staging after CT staging is that it identifies  CT 
occult Metastatic  diseases in 23% to 37% of patients.
PERITONEAL CYTOLOGY
Cytologic analysis of peritoneal fluid obtained by peritoneal lavage may identify occult 
carcinomatosis. Patients with positive peritoneal cytology findings have a prognosis similar to 
that of patients with macroscopic visceral (or) peritoneal disease(3 – 9 month median survival)
LYMPHATIC MAPPING:
Gives the essential role of nodal status in gastric cancer staging. Mapping agents such as 
radiocolloid with (or)  without vital dye and activated carbon particles have been used. The 
identification rate varies from 90% from 100%.
POSITRON EMISSION TOMOGRAPHY:
Positron emission tomography, estimate tumour metabolism on the basis of the uptake 
of radiotracer – flurodeoxyglucose – used a staging tool for gastic cancer. This technique may 
reveal CT-occult metastases and may be  used to  assess response to Neoadjuvant therapy.
TUMOUR MARKER
CA 72-4 is  highly specific  to gastric  cancer  and may be more reliable as  a  tumour 
marker than CEA for gastric cancer. Elevated level of CA 72.4 is more frequent than CEA in 
stage III, IV patient  and with  Peritoneal metastasis.
H. PYLORI TESTS.
Tests Sensitivity Specificity
Histology (Geimsa  stain)  93-99%  95-99%
Culture     72-92% 100%
Urease test   89-98% ;     93-98%
Urea breath test                95-98%   95 -98%
Serology  ELISA             88-89%      86-95%
PCR             95% 95%
Stool antigen test               95-99% 90-95
SURGICAL TREATMENT
EARLY GASTRIC CANCER
Endoscopic Submucosal Resection
For mucosal cancers, approximately 3% will be expected to have positive lymph nodes 
and selectively justify the use of an endoscopic submucosal resection (ESMR). Patients with 
submucosal  cancer,  where  the  risk  of  nodal  positivity  can  reach  20%,  would  be  better 
considered  for  limited  laparoscopic  resections  or  limited  open  operations.  Lymph  node 
metastasis  in  both  these  situations  is  associated  with  larger  tumor  size,  undifferentiated 
histology, and the presence of histologic lymphatic or blood vessel invasion. As a working rule 
lymph node metastases are rare if the tumor is less than 2 cm in diameter and well differentiated 
regardless of the depth of mucosal invasion.
Laparoscopic Resection
Laparoscopic  resection  is  being  used  increasingly  for  early-stage  cancer.  This  is 
performed  essentially  by  an  extragastric  approach  after  appropriate  tattooing  of  the  lesion 
endoscopically  so  as  to  ensure  the  ability  to  identify  the  lesion  and  the  adequacy  of  the 
resection. The procedure can be prolonged, and it is essential that clear margins be obtained. 
Progressively more advanced procedures such as distal gastrectomy are being performed with 
the laparoscopic hand-assisted approach using a minilaparotomy
Proximal tumours
 This  tumours  accounts  for  about  50% of  all  gastric  carcinomas.  These  tumours  are 
usually advanced at presentation and associated with poorer  long   term  prognosis.
Siewert classification of OG junction tumours
Type I : Associated with Barrett oesophagus (or) true
esophaged cancer growing into the OG junction
Type II : True junctional  tumours  that lie within 2cm of 
squamo columnar junction.
Type III :   Cancer within subcardial region of stomach. 
Type І : Treatment option for this tumour is oesophageal
resection with 10 cm margin clearance.
Type ІІ : oesophago gastrectomy
Type ІІІ : Total gastrectomy   with reconstruction
          There is no evidence that an extended gastric resection above and beyond complete 
clearance of  the primary tumor improves  survival;  i.e.,  total  gastrectomy does not  improve 
survival over distal or proximal gastrectomy, provided that the tumor is removed completely 
with negative transection margins (R0 resection). The extent of the gastrectomy therefore is site-
dependent and focuses on complete removal of the gastric carcinoma with preferably a 4- to 5-
cm margin  from the  gross  edge  of  the  tumor.  Clearly,  anatomic  limitations  influence  this 
margin because in antral lesions close to or involving the pylorus, only a limited portion of the 
duodenum can be removed. In similar fashion, a lesser extent of uninvolved esophageal margin 
may be acceptable provided complete histologic resection is possible.
Midbody Tumours
These account for 15% to 30% of all gastric cancers.
Treatement  option  for  this  tumours  also  total  gastrectomy  with   regional 
lymphadenectomy.
Distal Tumour
These tumours  account for approximately 35% of all  gastric  cancer.  The standared 
operation for these lesions is distal subtotal gastrectomy with appropriate lymphadenectomy. 
Subtotal gastrectomy entails resection of approximately three  fourths of the stomach, including 
the majority of lesser cuvature.
Extended  organ  resection  is  reserved  for  patients  with  apparently  node-negative  T4 
lesions,  in  which  complete  resection  requires  resection  of  the  invaded  portions  of  the 
diaphragm, pancreas, spleen, adrenal gland.
SURGERY
TOTAL GASTRECTOMY:
( If  the  tumour  involves the  stomach  diffusely or arises  in  the  body of the stomach 
and extends to within 6 cm of the cardia or distal  antrum)    Removal  of  stomach  with 
greater  &  leeser omentum along  with   nodes  en  bloc  with  Roux  en   y   reconstruction. In 
a     total  gastrectomy,  early  mobilization  of  the  left  lateral  segment  of  the   liver  will  be 
necessary to evaluate the extent of a more proximal lesion .However, once the right side of the 
esophagus is isolated, then theesophagus can be encircled, and the left paracardial nodes and 
the  paraesophageal nodes can be reflected inferiorly with the specimen In  this situation, the 
short gastric vessels need to be divided. The left crus is skeletonized, and the left adrenal gland 
is  identified  commonly  ,transect  the  stomach  with  the  placement  of  a  proximal  Satinsky 
vascular clamp, which allows ready stabilization of the esophagus In proximal lesions, a frozen 
section of the esophageal margin is performed. In locally invasive extensive proximal lesions, 
the  mucosal  margin  can  be  benign,  but  extraesophageal  extension  can  be  found  in  the 
periserosal tissues. Once this specimen is removed, the jejunal loop is isolated and divided with 
the GIA stapler .The small intestine for the Roux-en-Y anastomosis is divided with the stapler. 
Attention should be paid to ensure adequate vascularity of the limb, and some require careful 
transillumination to be sure that the arterial arcade is maintained without subsequent tension. 
The  reconstruction  can  be  performed  by  a  direct  end  of  
SUB TOTAL GASTRECTOMY WITH BILLROTH – II - ANASTAMOSIS
       
ROUX EN Y   OESOPHAGO JEJUNOSTOMY
               
esophagus to jejunum anastomosis It is helpful in the sutured anastomosis to place a single 
stabilizing suture in the posterior aspect of the esophagus, suturing the posterior aspect to the 
posterior surface of the jejunum, which stabilizes and aligns the appropriate. An alternative 
reconstruction uses the EEA stapler .
 
PROXIMAL GASTRECTOMY
An simple midline incision is made in the  abdomen
The left lateral segment of the liver is taken down and retracted, the esophageal hiatus is 
identified, and the soft  tissue around the diaphragmatic hiatus is  incised. The extent of the 
lesion is appreciated rapidly, and on occasion, local invasion into the crura of the diaphragm 
may need crural resection. The retroperitoneal attachments to the diaphragm on the left side 
then are incised, coming down toward the anterior surface of the left adrenal gland. Once the 
esophagus is mobilized, it can be retracted upward and forward, and a decision can be made as 
to the extent of resection required.
For cardiac lesions that are locally extensive, the spleen is mobilized and taken with the 
specimen. In more localized lesions,  the short gastric  vessels are taken close to the splenic 
hilum to enable greater mobilization. On the right side, the right crus is cleared, and all tissue is 
taken back to the celiac axis  origin.  The section then is  carried forward along the anterior 
surface  of  the  celiac  axis  to  identify  the  left  gastric  artery. In  the  majority  of  
PARTIAL GASTRECTOMY
                            CUT SPECIMEN OF    CA  STOMACH
patients, all lymph nodes along the lesser curvature can be dissected readily and reflected back 
toward the proximal gastrectomy with the specimen. Care must be taken not to devascularize 
the lesser curvature. An appropriate distal site on the greater curvature is identified, and the 
stomach is divided with two passages of the GIA-60 or TA stapler. This can be done in an 
oblique fashion so as to create a relative tube of the distal stomach .
SUB TOTAL GASTRECTOMY
 (If  the   proximal  luminal resection  margin   is 5- 6 cm)  .Removal of   80%  of  distal 
stomach     leaving  the  short  gastric  vessels  intact   to   ensure   splenic 
preservation.Reconstruction is  by   either  roux en  y  or  billroth  ІІ   or  polya.
DISTAL GASTRECTOMY:
( Antral growth  with   5cm  marginal  clearance ) .Removal of  less than   80%  of 
stomach   with  reconstruction.
PALLIATIVE   PROCEDURES
(For   advanced gastric cancer  to minimize  bleeding   and gastric out let obstruction)
• Gastrectomy 
• Anterior  gastro jejunostomy
• Laser or argon  beam  tumour  ablation  with laser  recanalization.
• Endoscopic  placement  of  coated  metallic  stents.
COMPLICATIONS  OF SUGERY:
The most devastating complication is anastomatic leak, which occurs in 3% to 21% of 
patients. Dumping syndrome will develop in 10% of patients.early dumping typically occurs 15 
to30 minutes after meal and includes diaphoresis,abdominal cramps, palpitations and watery 
diarrohea. Late dumping is usually associated with hypoglycemia and hyperinsulinemia. The 
management include dietery habits and if refractory, a somatostatin  analog.
Other complications are 
• Bleeding – 0.3-5%
• Pulmonary 3-55%
• Infection  3-22%
• Anastomotic  leak  3-21%
• Cardiac 1-10%
• Renal 1-8%
• Pul. Embolus -1-4%
OUT COME OF SURGERY
The  overall  5  yr  survival  rate  is  10-21  percent  who  undergo  potentially  curative 
resection  has a slightly better prognosis with a 5 year survival rate of 24% to 57%. The 5 year 
survival rate who under go curative resection is 50% .The overall locoregional recurrence rate 
was 38% the median time to death from the time of recurrence was 6 months. 
Neoadjuvant therapy
The advantages  of  Neoadjuvant  chemotherapy is decreased tumour seedling at surgery 
and tumour sensitivity to a chemotherapeutic regimen.drugs used are  etoposide, cis platin, 5-
fluro uracil . The clinical response rate of combination of etoposide ,cisplatin and  5Fu  range 
from  21% - 31%.
Adjuvant chemo therapy
The adjuvant chemotherapy of  5Fu  was   associated with  a  survival  benefit  of  95%.
Post  op External  beam Radiation therapy
The combination of 5Fu with 40gy external beam radiation therapy versus RT alone 
showed improved survival. The three year survival rate for chemo RT were 52% compared to 
surgery only group   40%
Management of Advanced Disease
About 20-30% patients present with stage IV disease. The 5yr survival rate for patients 
with  stage  IV  disease  is  zero.  Because  of  this  low  cure  rate  and  advanced  disease  at 
presentation, palliation is an essential component of gastric cancer Management.
Palliative surgery
Surgery  achieves  good  palliation  less  than  50%of  the  tome.  The  procedure  include 
palliative  Distal gastrectomy with  acceptable mortality  rates. Palliative total gastrectomy & 
esophago gastrectomy should be approached with greater caution because the morbidity from 
these procedures is higher 4%.
Palliative chemotherapy
The Combination regimen included FAMTX(5Fu, doxorubicin, Methotrexate) FEMTX 
(5Fu, epirubucin, Methotrexate) and ELF(etoposide, leucovorin, &5Fu) patients who received 
combination chemotherapy had better survival.
Pallative Radiation therapy:
No large prospective trial has demonstrated a long term benefit  from  radiation  therapy.
Palliation by Endoscopic means include laser recanalisation (or) simple dilation with 
(or) without  stent placement can be used to treat obstruction.
Intraperitoneal Hyperthermic Perfusion
This   procedure  is  a  combination  of  hyperthermia  & Mitomycin  C.  Fujimoto  et  al 
reviewed that  patients  treated with perfusion survived  longer(1 year survival  rate  80% vs 
34%).
CA STOMACH WITH  LIVER SECONDARIES 
OESOPHAGOJEJUNOSTOMY
Immunotherapy
Machara et al reported a combination of  chemotherapy and intraperitoneal  injections of 
OK-432  had  a  long   survival  rate.  Other  immunotherapy’s  are  mycobacterium  derived 
polysaccharides.
Gastric Lymphoma
The Stomach is the most common site of lymphoma in GIT.  The average age of patients 
is 60 years.the most frequent site ofpresentation are pain, weight loss,bleeding and fatigue. 
H.Pylori appears to be a causative agent is the development of gastric lymphoma and MALT 
lymphoma.  Endoscopy detect  the lesion is 80% of cases as sub mucosal infiltration.Other Lab 
test include lactate dehydrogenases  and B2 Micro globulin determination.  The pathological 
type of NHC is  B cell Type & diffuse histiocytic type. Treatment include Acid Suppression 
therapy, Metrogyl and Antibiotic.Anti H. PYLORI treatment is necessary for eradication of H. 
p ylori. External beam irradiation and chemo therapy is offered to those who do not respond to 
an antiobiotic eradication and high risk patients.  Gastric resection is rarely performed for pt. 
with  MALT  lymphomas.surgery  is  necessary  in  some  cases  to  confirm  diagnosis.Surgical 
resection is   curative in patients  with localized disease,  although  half  of  resected patients 
require  chemotherapy.If surgery is performed,an attempt is made to resect the area grossly 
involved with lymphoma but leave grossly  normal stomach intact. Negative margins are not 
necessary for cure. Surgery alone produces survival rate of 82%, where as radiation therapy 
produces  five year survival rate of only 50%. 10- year survival rates  of 80% have been seen in 
patients with Ann Arbor staging of stage ІE  and Stage ІІ .Patient with lymphoma  are initially 
treated  with  chemo  therapy  of  CHOPP   regimen.  Radiation  and  surgery  are  reserved  for 
patients  who do not have a complete response to chemotherapy.
Gastric Carcinoid
Gastric  carcinoid  constitute  only  2%  of  carcinoid  tumors.  gastric  carcinoids  are 
classified into three types .  Type І  carcinoids are associated with type A chronic atrophic 
gastritis,  Type  ІІ   carcinoids are associated with Zollinger-Ellison  syndromewith multiple 
endocrine  neoplasia  syndrome-І,  and  type   ІІІ   are  sporadic  gastric  carcinoids.  Type  І 
carcinoids  are the most common type of gastric carcinoid and are found predominantly in 
women. These patients have typically have elevated plasma gastrin levels and  low gastric acid 
production. Type ІІ  gastric carcinoids are the least common type, accounting for 8% of cases 
with  an  equal  distribution.  Even  they  are  associated  with  Zollingar  Ellison  syndrome  in 
conjunction with MEN- І  they share features with type -1 carcinoids,such as location in the 
fundus, multricentricity, elevated plasma gastrin  level and small size.Type ІІІ  carcinoids , 
which are sporadic carcinoids, represent  23% of cases and are  found predominantly  in men; 
The mean age of patients at diagnosis is 49 years. Patient may complain of histamine producing 
symptoms,  such  as  cutaneous  flushing,bronchospasm,itching  and lacrimation.  The  sporadic 
tumours are  single, solitary ,large and located in the antrum or fundus of stomach. The natural 
course  of type ІІІ  carcinoids is more aggressive with hepatic metastasis  found at diagnosis in 
upto  50% of cases.
           Gastric carcinoids are diagnosed by both biochemical and histologic means. Upper 
gastrointestinal  endoscopy, including endo ultrasound, is also essential to evaluate the number, 
size ,extent  and location of lesions. Extensive gastric biopsy  should be performed in those 
with  suspected  gastric  carcinoids,  checking  for  histologic   chromogranin,  features  of 
dysplasia,mucosal  atrophy,and  the  degree  of  mucosal  invasion.it  appears  that  the  rate  of 
diagnosis correlates with the number of biopsys performed.CT of the abdomen is essential to 
exclude  metastasis to the liver and nodal involvement.
The type of gastric carcinoid  dictates the  nature of treatment  .for patients with either 
type   І or type ІІ  carcinoids and with tumours less than 1 cm or with fewer than three to five 
lesions,  treatment  typically  consists  of  an  endoscopic  polypectomy or  endoscopic  mucosal 
resction.Antrectomy or local excision may be performed in a young patient with an elevated 
gastrin  level  who has recurrent or multifocal disease..  This treatment will  decrese  gastrin 
levels and frequently  leads to  the regression of the tumours. Older patients with many lesions 
may  be  followed  if  the  lesions  are  small.  For  diffuse  or  recurrent  disease,  a  completion 
gastrectomy  may  be  recommended,  depending  on  the  patients  age  and  course  of  the 
disease.Type ІІІ disease should be considered for en bloc resection with  lympadenectomy, 
depending on the tumour size.It appears that five year survival rate  for patients  with type І and 
type ІІ  gastric  carcinoids are between 60% and 75%.in contrast,  the five  year survival   in 
patiets   with type ІІІ  gastric carcinoids  is less than 50%. Follow up in patients with gastric 
carcinoids primarily consists of plasma chromogranin  estimation. Plasma gastrin and urinary 
5-HIAA levels may also be evaluated, although urinary 5-HIAA  levels. 
GASTRO INTESTINAL STROMAL TUMOURS 
GISTs are the most common mesenchymal tumors of the stomach, with the stomach 
being the most common location of these tumors in the gastrointestinal tract (40%), followed by 
the small  intestine (32%). GISTs of the stomach are predominantly found in males,  with a 
median age at diagnosis of 63 years. The presenting features in these patients are varied and 
include bleeding (38%), abdominal pain (11.8%), and rupture (1%); 12% of patients have no 
symptoms. The median size of GISTs of the stomach is 6 cm.
Regardless of the location of  these tumors in the stomach,  R0 resection remains the 
treatment of choice, conferring a 5-year survival of 55%. Several studies have shown that the 
features recommended in the NIH guidelines, tumor size (>5 cm) and mitotic index (>5/50 hpf), 
are associated with a less favorable outcome. Tumor location in the gastroesophageal junction 
or fundus, ulceration, coagulative necrosis, and mucosal invasion were found to be associated 
with  a  poor  outcome  .Antral  tumors,  however,  were  found  to  be  associated  with  a  more 
favorable outcome .Those patients with unresectable or metastatic disease are offered treatment 
with Imatinib (Gleevec, an oral tyrosine kinase inhibitor). They may then be  re-evaluated  for 
potential resection if they demonstrate response to  treatment. 
OBSERVATION
 Cancer stomach is one of the commonest abdominal  malignancy in our region.
 The incidence of distal growth continues to be increasing in our region.
 The incidence of CA stomach in distal part  usually present with age above 50yrs.
 Cigarrete smoking showed increase in proximal cancers when compared   distal cancers.
 The association between Blood group A and Carcinoma Stomach correlate with the study of 
AIRD ET AL.
 Endoscopy and Biopsy have a high sensitivity in picking up all subsite growths. 
 The intestinal type and in association with distal growth  have a favourable prognosis in 
operable cases.
 Stage 4 disease is common in proximal cancers which shows poorer prognosis  in over all 
survival
 Gastrectomy with its acceptable morbidity  is associated with good quality of life, whenever 
the tumour is operable
 Total Gastrectomy carries a high morbidity and mortality when compared to subtotal and 
partial Gastrectomy
CONCLUSION
 The causes of Distal stomach cancer continues to be commoner than    proximal  cancers 
among  Indians.
 The Etiology of carcinoma stomach tends to be  different etiology  in both proximal and 
distal cancers.
 H.Pylori has a 45 .5% association of ca stomach and it is mostly associated with distal 
growths.
 Endoscopy has a high sensitivity in detecting all subsite growths but least sensitivity in 
detecting early cancers. 
 Most cases  present with stage 4 disease which  shows   absence of screening of this 
disease.
 Curative subtotal and distal gastrectomy is associated with good quality of life whenever 
the tumour is operable.
 Mortality is due to increase in duration of  surgery  and  associated   co-marbid illness 
and   anastomotic  leak.
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No Name Rel IPNo.
Age/ 
Sex SE SM AL Diet Subsite Pain
Vom/
DYSP
HAGIA
Mass L/N L/A
1 Asokan H 17640 65/M 800 √ √ M Antrum √ √ √
2 Pattanaasari H 47730 60/M 800 M Antrum √ √ √
3 Gurusamy H 30628 50/M 800 M Antrum √ √
4 Rajammal H 28355 50/F 800 M Antrum √ √ √
5 Kalliammal H 33605 55/F 800 M Antrum √ √ √ √
6 Pillaikani H 21600 54/M 800 √ M Antrum
7 Mayillappan H 14828 64/M 800 √ M Antrum √ √ √
8 Ayyadurai H 2733 45/M 800 √ √ M Antrum √ √ √
9 Palaniappan H 281395 62/M 800 √ √ M Antrum √ √ √ √
10 Muppidathi H 35131 55/M 800 M Antrum √ √
11 Muhtukutti H 19729 49/M 800 M Body(LC) √ √ √ √
12 Murugan H 26428 55/M 800 √ √ M Antrum √ √ √ √ √
13 Babu H 36204 67/M 800 √ M Antrum √ √ √
14 Muthiahdevar H 35208 65/M 800 √ M Body(GC) √
MASTER CHART
15 Thiraviampillai H 5705 70/M 800 M Antrum √ √ √ √
16 Ravikumar H 37841 24/M 800 M Antrum √ √
17 Mohammed m 36686 47/m 800 √ √ fat antrum √ √
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1. √ A+ve Antral wall  thickening Antral GrowthGoo Adeno ca
Antral Growth
LN+ Fixed to Panreas
2. √ AB+ve Antral wall  thickening AntralGrowth Goo Adeno ca
Antral Growth Liver 
2° Ascites
3. √ O+ve (N) AntralGrowth Adenoca
Antral Growth
Mesentric
deposits
4. √ 
(E)
√
B+Ve (N) (N) - Growth Antrum
5. √
(RHC)
√
AB+ve Antralwall thickening2° Liver Ascites
Antral
Growth Adeno ca
Growth Antral
2° Liver
Acites
6. √ √
(E)
√
AB+ve
Antralwall
thickening AntralGrowth Adeno ca
Antral Growth
LN6
7. √ √ B +ve
Antralwall
thickening
para ao rtic LN
Antral
Growth
Antral Growth
LN fixed to pancreas, 
TC, PA, PD,Ascites
8. √ B+ve Antral wall thickening Antral growth Adeno carcinoma
Antral Growth
LN infiltration to 
pancreas
9. √ √ B+ve Dilated stomach Pre pyloriculcer Adeno carcinoma
Antral Growth
Perigastric
LN
10. √ B+ve Duodenal thickening Antral Growth & Goo Adeno carcinoma Antral Growth LN
11 √ B +ve Antral wall thickening GOO Adeno carcinoma
Growth LC
Pancreas infiltration, 
LN
12
RHC √ 3cm B +ve
Antral wall thickening,
PALN,2°Liver
Antral Growth & 
Goo
Growth LC
Pancreas infiltration, 
TC,LN,ASCITES
13
E √ O+VE Antral wall thickening Antral Growth
Antral Growth
Mesentric
deposits
14
E
√
A +ve Growth BodyAscites 2° liver Growth Body Adeno carcinoma +
Growth Body
Ascites 2
15
E
√
O +ve Antral wall thickening,PALN, Pyloric Antrum Adeno carcinoma
Growth Antrum fixed 
to pancreas, TC,LN 
Mesentric
deposits
16. √ LHC A +ve N Antral Growth Poorly differentiatedAdeno carcinoma
Growth Antrum fixed 
to pancreas, TC,LN
17
18 Natarajan H 39830 58/M 800 √ √ M CARDIA √ Dysph
agia
√
19 Samuvel C 35767 50/M 800 √ √ M Antrum √ √
20 Mariappan H 14578 64/M 800 √ √ M Antrum √
21 Muthiah H 23988 57/M 800 √ √ M Antrum √ √ √
22 Shanmugavel H 27093 61/M 800 √ M Antrum √ √ √
23 Muthiahdevar H 26818 61/M 800 √ √ M Antrum √
24 Soundarrajan H 27778 40/M 800 M Antrum √ √
25 Balaiah H 21981 55/M 800 √ M Antrum √ √ √
26 Vellammal H 3988 55/F 800 M Antrum √ √ √ √
27 Velu H 15037 68/M 800 M Antrum √ √ √ √
28 Ramakrishnan H 51154 60/M 800 M Antrum √ √ √
29 Kanagaraj H 18898 45/M 800 √ √ M Antrum √ √ √ √
30 Velkani C 18974 52/F 800 M Body(GC)
LINITIS
√ √ √ √
31 Seenidurai H 20148 50/M 800 √ √ M Body
LINITIS
√ √ √ √
32 Muthupandi H 24804 65/M 800 √ M Antrum √ √ √
33 Lakshmi H 30615 50/F 800 M Antrum √ √ √
34 Narayanan H 21064 60/M 800 M Antrum √ √ √
35 Ganapathi H 14009 50/M 800 √ M Antrum √ √ √
36 Alphonse C 13893 50/M 800 M Antrum √ √ √
18 √ √
O+ve Mass body of stomach BodyLC
Growth Antrum fixed 
to pancreas, TC,LN 
Mesentric
deposits
19 √ √ O+ve Ectopic KidneyGB Calculus
Growth
Antrum
Growth Antrum fixed 
to pancreas, TC
20 √ B +ve DistendedStomach
Growth
Antrum
Growth antrum
LN
21 √ √ O+ve Antral wall thickening GrowthAntrum
Growth Antrum fixed 
to pancreas,coeliac
22 √
E
√
O +Ve Antral  GrowthPALN
Growth
Antrum
Poorly differentiated
Adeno carcinoma
Growth Antrum fixed 
to pancreas,LN
23
E √ O+ve
Antral wall thickening
2°Liver GrowthAntrum Adeno carcinoma
Growth
Antrum2
LN,Ascites
24 √ A+ve N AntralGrowth
Growth Antrum 
mesenteric
LN, Ascites
25
E
4c
m
√ O+ve
Antral wall thickening
2°Liver
Ascites
Antral
Growth
GOO
Growth Antrum, 2
Ascites
26 √ E √ A+ve Antral wall thickening
Antral
Growth
GOO +
Growth Antrum Fixed 
to TM
27 √ E √ B+ve DuodenalPathology
Antral
Growth
Growth Antrum gross 
Ascites
fixed
28 E √ B+ve
Antral
Wall
thickening
Antral
growth
Growth Antrum
LN Al to TC
29
LHC √ AB+ve Antral growth LN ascites + Anthralgrowth
Poorlydiffer
Adeno carcinoma
Growth
Antrum 2
LN+
30 √
LHC
√
AB+ve ascites
Anthral
Growth,
Linnitus,
plastica
Poorlydiffer
Adeno carcinoma √
Contracted thickened
Stomach LNO
Ovary  infil.
31 √ E(RHC) √ A +ve Massepigastrium
Linitis
Plastica
Adeno ca √ Antral GrowthBody to Antrum
32 √ E
4 
cm
B+ve Antral Wallthickening
Antral
Growth
Mucinous
Adeno ca Antral Pyloric Growth
33 E AB+ve Antral WallThickening,2° liver
Antral
Growth
2°Liver
Antral Growth PALN
34 √ E √ AB+ve
Antral
Wall
LN, Ascites +
Antral
Growth
Antral Growth
to Body fixed to 
pancreas, TC,LN
35 √ E √ A +ve Ascites GOOMRD
Antral
Growth Adeno ca
Growth Antrum
Ascites
36 √
O+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth
37 Shamugathai H 37868 58/F 800 M Antrum √ √ √
38 Sudalai H 39760 74/M 800 √ √ M Antrum √ √ √
39 Arunachalam H 3095 60/M 800 M Antrum √ √ √
40 Vedhamanikam H 49220 55/M 800 M Antrum √ √ √
41 Thirumaki H 16078 63/M 800 √ √ M Antrum √ √
42 Ramalakshmi H 22240 47/M 800 M Antrum √ √ √ √
43 Dharmar H 36087 58/M 800 √ √ M Antrum √ √ √ √
44 Thirumalai H 16078 63/M 800 √ √ M Antrum √ √ √ √
45 Ramaih H 27873 40/M 800 √ M Antrum √ √
46 Grace C 18080 45/F 800 M Antrum √ √
47 Andidevar H 31637 60/M 800 √ M Antrum √ √ √
48 Narasiman H 9276 55/M 800 √ M Antrum √ √ √
49 Nagalingam H 25936 54/M 800 √ M Antrum √ √ √ √
50 Rawathy H 28113 50/F 800 M Antrum √ √
51 Ramachandran H 52332 40/M 800 M Antrum √ √ √
52 Muthammal H 33603 57/M 800 M Antrum √ √ √
53 Ayyanu H 50078 65/M 800 √ √ M Antrum √ √ √ √
54 Msooth M 31106 60/M 800 √ M Body(GC) √ √ √
55 Subbiah H 36270 75/M 800 √ √ M Antrum √
37 √
LHC O+ve 2° liver AntralGrowth
Mod. diff
Adeno ca
Antral Growth
2° liver Fixed to T4 
pancreas
38 √ √ O+ve
Antral
Wall
Thickening,Ascites
Antral
Growth
Antral Growth
Fixed to 2
Ascites
39
E √ O+ve
Antral
Wall
Thickening
Antral
Growth
Goo
Adeno ca Antral GrowthFixed Post LN
40 √
O+ve
Antral
Wall
Thickening
Antral
Growth Adeno ca Antral Growth
41 √ E √
B+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth 
Perigentric LN
42 √ E √
B+ve
Antral
Wall
Thickening
Antral
Growth Antral Growth CN
43
E O+ve
Antral
Wall
Thickening
Antral Growth PH
44
E √ A+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth Ascites 
mesenteric
LN
45 √ B+ve N AntralGrowth Adeno ca
Antral Growth
46 √ B+ve N AntralGrowth Adeno ca Antral Growth LN
47 ERHC √ A+ve AntralThickening ascites +
Antral Adeno ca Antral Growth LN Ascites
48
E
4 
cm
AB+ve AntralThickening Liver Ascites Antrum
Poorly Diff
Adeno ca
Antral Growth 2
Liver ascites
49
E
3 
cm
B+ve AntralThickening Antrum
Antral Growth 2
Liver LN + PD+
50 √ E √
3c
m
AB+ve AntralThickening 2° Liver Antrum Adeno ca
Antral Growth LN 
2°Liver with 2
Pancreas
51 √E O+ve AntralThickening Antral Growth Antral Growth 2
52
√E √ AB+ve 2° Liver ascites Antrum Body Antral ascites fixed to pancreas TC
53 √ √ B+ve AntralThickening Antral Growth Antrum 2
54 √ E E AB+ve AntrumThickening 2˚liver N
Antrum  Body 2
LC
55 √ O+ve Ascites R+PlEffu……….. N
Antrum 2
LN
56 Muthah ayyar H 31878 67/M 800 √ V Antrum √ √ √
57 Durairaj H 25389 56/M 800 √ √ M Antrum √ √ √
58 Muthiah H 218324 84/M 800 M Antrum √ √ √ √ √
59 Sudalai H 14342 64/M 800 √ M Antrum √ √ √ √
60 Sankaranaryan H 38225 35/M 800 √ √ M Antrum √ √ √ √
61 Yesuvadian C 3550 65/M 800 √ √ M Antrum √ √ √ √
62 Ramasubhu H 20315 55/M 800 √ √ M Antrum √ √
63 Subramanian H 19426 70/M 800 √ √ M Antrum √ √ √
64 Muthusamy H 91484 45/M 800 √ √ M Body(Gc) √ √
65 Murugan H 20326 50/M 800 √ √ M Cardia √ Dysph
agia
√ √ √
66 Narayanan H 19252 45/M 800 √ √ M ANTRUM √ √
67 Abraham C 21382 54/M 800 √ √ M AntrUM √ √ √
68 Mahalingam H 24529 38/M 800 √ √ M Antrum √ √
69 Jeyankani H 14206 48/F 800 M Body(LC) √ √ √
70 Rangitham H 22236 46/F 800 M Body(GC) √ √
71 Paramasivan H 20313 60/M 800 √ M Antrum √ √ √
72 Ramasubbu H 4298 43/M 800 √ M OG jn √ Dysph
agia
73 Ganapathy H 40239 72/M 800 M Body(GC) √ √
74 Arumugam H 30803 58/M 800 √ M Antrum √ √ √
56 √ E
2 
cm
O+ve Antrum Thickening 2˚ liver ascites Antral Growth
Antrum Ascites 2
liver post. fixed
57
E
2c
m
√ O+ve AntrumThickening 2˚liver Antral Growth
Antrum Ascites 2
liver
58 √ E
4c
m
√ B+ve Antral2˚liver LN Antral Growth
Antrum 2
Ascites
59
E
3c
m
AB+ve Antrum 2˚LiverLN Antral Growth
Antrum 2
LN Ascites
60 √ B+ve Antralwall thickening Antral Growth
Antrum
LN
61 √ E √ B+ve Antralwall thickening Antral Growth Adeno ca Antral GrowthLN+ Fixed to Panreas
62 E √ O+ve Antralwall thickening AntralGrowth Adeno ca
Antral Growth  LN 
mesenteric deposits
63 √ E E √ B+ve Antralwall thickening ln +
Antral
Growth Antrum LNAscites
64 LHC
AB+Ve (N) Growth BodyGC
FNAC LN
Adeno ca Growth Body
65 √ E A+ve (N) Fundal growth Growth Fundus
66 √ E √ B+ve Antral growth AntralGrowth
Adeno ca Antrum   to 5m below
67 √ √ O+ve
Antral
thickening AntralGrowth
Adeno ca Antral LN 2
68 √ AB+ve Normal Body LC Adeno  ca BodyLC
69 E A +ve Growth BodyLC Adeno  ca
Body LC
LN
70 O+ve Antral wall thickening BodyLC
Body LN
71 E √ A+ve Antral wall thickening AntralGrowth Adeno ca _ Antrum PD, MD
72
E AB+ve N Cardiac Growth Adeno ca Cardia
73 E A+ve Antral wall thickening BodyGC Adeno ca + Body GC Ascites +
74 E A+ve Antral wall thickening Antrum Adeno ca Antral Growth fixed to Pancreas, LN ascites
75 Murugan H 25549 49/M 800 √ M Body(GC) √
76 Lakshmi H 99969 47/F 800 M Antrum √ √ √
77 Ganapathy H 32797 62/M 800 M Antrum √ √ √
78 Subbiah H 23465 65/M 800 √ √ M Antrum √ √ √ √
79 Shanmugam C 26217 60/F 800 M Linitis 
plastica
√ √
80 Kandiahdevar H 49520 60/M 800 √ M Antrum √ √
81 Mani H 17314 60/M 800 √ M Antrum √ √ √
82 Ganapathy H 31909 66/M 800 √ M Antrum √ √ √
83 Narasingamal H 21870 30/F 800 M Antrum √ √
84 Mani H 17414 60/M 800 √ √ M Antrum √ √ √ √ √
85 Sappani H 49413 43/M 800 √ M Body(GC) √
86 Subramani H 17575 55/M 800 √ √ M Antrum √ √ √
87 Mariammal H 39539 67/F 800 M Body(GC) √ √ √ √
88 Ganapathy H 60604 67/M 800 √ √ M Antrum √ √ √ √
89 Manivelraj H 5434 40/M 800 √ √ M Antrum √ √ √ √ √
90 Valliammal H 57286 65/F 800 √ √ M OG JN √ Dysph
agia
√
91 Thriumalai H 34679 67/M 800 √ √ M Antrum √ √
92 Arjunan H 37623 50/M 800 √ M Antrum √ √ √
93 Thayammal H 33860 55/F 800 M CARDIA Dysph
agia
√
75 E
O+ve Antral wall thickening BodyGC Adeno ca
Body
GC
LN
76 √ B+ve Antral wall thickening Antrum Antrum
77 E O+Ve Antral wall thickening Antrum Poorly differentiated Adeno ca
Antrum
TC
78
E
2 
cm
A+ve Antral wall thickening, 2˚ Liver PALN
Antral
Growth Antrum 2
79 E √ O+Ve Antral wall thickening, 2˚ Liver Adeno ca 2˚ Liver Ascites
80 E √ A+ve Antral wall thickening, 2˚ Liver
Antral
Growth Adeno ca Antrum 2
81 √ √ O+ve AntralThickening ascites
Antral
Growth Antrum Ascites +F
82 √ E B+ve Antral wall thickening AntralGrowth
Adeno ca
Well differentiated Antrum LN
83 √ B+ve Antral wall thickening AntralGrowth Antrum LN
84 √ E √
4c
m
√ A+ve Antral wall thickening AntralGrowth Antrum +LN,+TC
85 E O+ve N CT BodyGC Body GC LN
86
E √ A+ve N GOO Adeno caWelldifferentiated
Antrum Ascites
PB MC
Roux en y
87 √ √ O+ve Antral wall thickening AntralGrowth Adeno ca
Body 
-----------------------------
88 √ E
2c
m
O+ve Antral wall thickening,2˚ liver
Antral
Growth
89
E
3c
m
√ B+ve Antral wall thickening AntralGrowth
90
E √ √ AB+ve N Body GC
Growth Body Ascites 
+PD +POH Int to 
pancrease
91 √ √ √ √ O+ve Free Fluid LN Antral Growth
Antral
Growth Adeno ca
Liver 2° Antral growth 
TC infiltration
92 √ √ √ √ B+ve Free Fluid LN Antral wall thickening
Antral
Growth Adeno ca
Growth Antrum 
Ascitic fluid Pelvic 
Deposits
93
√
3c
m
B+ve Hepatomegaly IHBR dilatation PH nodes
Growth
Body of stomach Adeno ca
Growth body of 
stomach 2° Liver PH 
nodes
94 Arumugam H 26655 52/M 800 √ √ M Antrum √ √ √
95 Thangaraja H 34538 60/M 800 √ √ M Antrum √ √
96 Muthusamy H 41489 45/M 800 √ M Body(GC) √ √
97 Petchikumar H 49496 73/M 800 √ √ M Antrum √ √
98 Venkatachalam H 49485 52/M 800 √ M OG JN Dysph
agia
√
99 Ganesan H 7903 64/M 800 √ √ M ANTRUM √
100 Pandi H 5161 45/M 800 M Body(GC) √
101 Selvaraj H 6158 57/M 800 √ M Growth 
Cardia
Dysph
agia
102 Syedmohamed M 31863 60/M 800 √ M Pyloric 
growth
√ √ √
103 Paramasivan H 29576 65/M 800 M Antrum √ √ √ √
104 Joseph C 36392 65/M 800 √ M Antrum 
Growth
√ √ √
105 Vairamuthu H 62501 60/M 800 √ √ M Antrum √ √ √
106 Ganesan H 7903 64/M 800 √ M Antrum √ √
107 Krishnan H 39822 65/M 800 √ √ M Antrum √ √ √
108 Abdulrahim M 40853 65/M 800 √ √ M Antrum √ √ √
109 Manivelraj C 51286 40M 800 √ √ M Antrum √ √ √
108 Perumal H 48604 35/m 800 √ √ m antrum √ √
111 Cristopher C 48670 45/M 800 √ M Body(LC) √ √ √
112 Mohamed 
bashir
M 36636 47/M 800 √ √ M Antrum √ √ √
94 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca + Growth antrum LN
95 √ √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Growth antrum LN
96 AB+ve Normal study Elevated  mucosal irregularity Growth antrum
97 √ √ √
2c
m
√ B+ve Ascites hepaticadenopathy AntralGrowth Adeno ca
2° Liver ascites 
Growth antrum 
Pancreas Infiltration
98 √ √ 3cm
√ B+Ve Liver 2° Growth OG jn √
Growth OG jn PH 
nodes
99 √ √ √ A+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN,TC 
infiltration
100 √ O+ve Liver 2° PH nodes GrowthBody of stomach Adeno ca
Growth body of the 
stomach PH nodes
101 √ √ A+ve N Cardiagrowth Signet ring type
Growth cardia 
LN,Omental deposits
102 √ √ √ √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth
103 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth
104 √ √ AB+ve Distended stomach AntralGrowth Antral Growth
105 √ A+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
106
√
Dvt 
Lt 
LL
A+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN TC 
infiltration
107 √ √ B+ve Distended stomach GrowthBody _ Growth body LN OD+
108 √ √ AB+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
109 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
110 √ √ √ O+ve N Body of Stomach Diffuse Thickening PD+OD ascites
111 √ √ √ B+ve N AntralGrowth Spindle cell ca
Growth Body
LN
112 √ √ AB+ve Antral wall thickening AntralGrowth
Antral Growth LN 
Ascites
113 Sermakani H 3927 38/F 800 M pyloric √ √ √ √
114 Ramar H 16634 48/M 800 √ M Antrum √ √ √ √
115 Anandha 
naryanan
H 25798 66/M 800 √ √ M Diffuse √ √ √
116 Thangaraj H 28985 42/M 800 √ √ M Antrum √ √
117 Maharaja H 32200 35/M 800 √ √ M Antrum √
118 Sermadevi H 33087 35/M 800 √ M Antrum √ √ √
119 Ramalingam H 26012 65M 800 √ √ M Antrum √ √ √ √
120 Thayammal H 33860 60/F 800 M Antral 
growth
√ √ √
121 Krishnan H 39822 65/M 800 M Antrum √ √ √ √
122 Abdulrahim M 40853 65/M 800 √ √ M Antrum √ √ √
123 Ganthimathi H 23160 70/F 800 M Antrum √
124 Arumugam H 26615 52/M 800 √ M Antrum √ √ √ √
125 Perumal H 28760 52/M 800 √ M Antrum √ √
126 Murugesan H 31863 62/M 800 √ √ M Antrum √ √ √
127 Ponnusamy H 34769 60/M 800 √ M Antrum √
128 Arjunan H 3762 57/M 800 √ √ M Antrum √
129 Thangalakshmi H 43811 57/F 800 M Antrum √ √ √
130 Sarumathy H 45465 40/F 800 M Antrum √ √ √
131 Murugan H 15161 31/M 800 √ M Antrum √ √ √
132 Krishnavel H 18433 31/F 800 M Antrum √ √ √
113 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
114 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
115 √ √ √ √ O+ve Ascites
Diffuse 
involvement 
stomach
P00rly diffadenoca √ Contracted stomach LN Ascites
116 √ √ B+ve Antral wall thickening AntralGrowth Antral Growth LN
117 √ √ A+ve Antral wall thickening AntralGrowth _ Antral Growth LN
118 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth LN
119 √ √ √ O+ve Antral growth Antral Growth LN
120 √ √ AB+ve Antral wall thickening Body and AntralGrowth Growth Body LN
121 √ √ √ O+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
122 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN 
Ascites
123 √ √ √ AB+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth 2° 
Liver Ascites
124 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca + Antral Growth
125 √ √ √ √ √ O+ve Ascites 2° Liver ? Linitis plastica Adeno ca √ Diffuse thickening
126 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
127 √ AB+ve Antral wall thickening AntralGrowth
Antral Growth Ascites 
LN
128 √ B+ve Antral wall thickening Growth Body Adeno ca Growth Body Antrum
129 A+ve Antral wall thickening AntralGrowth Adeno ca + Antral Growth
130 O+ve N AntralGrowth Serosa not involved
131 √ √ √ O+ve Antral wall thickening AntralGrowth Adeno CA Antral Growth LN
132 √ B+ve N AntralGrowth Adeno CA Antral Growth LN
133 Thangathai H 29312 50/F 800 M Body of 
Stomach
√ √
134 Nallamadan H 51675 70/m 8oo M Antral 
growth
√ √
135 Vellammal H 30566 70/F 800 M Body of 
Stomach
√ √ √ √
136 Thangaraja H 34538 60/M 800 √ √ M Growth 
Antrum
√ √ √
137 Selvaraj H 50590 65/m 800 √ √ M Pyloric 
growth
√ √
138 Avudaithai H 34221 45/F 800 M Growth 
Antrum
√ √
139 Nainarammal H 8591 50/F 800 M Growth 
Antrum
√ √
140 Deivakirubai C 25414 35/F 800 M Growth 
Antrum
√ √ √ √
141 Marial c 48067 50/f 800 M antrum √ √ √
142 Lashmanan H 35426 62/f 800 √ √ M ( F) cardia √ Dysph
agia
143 Chandran H 7148 41/F 800 CARDIA √ Dysph
agia
144 Jamilal M 26987 53/F 800 FATTY 
MEAL
Growth
Og jn
Dysph
agia
√ √
145 Parwathy H 27625 45/m 800 M CARDIA Dysph
agia
√
146 Malliga H 38154 38/F 800 M OG JN Dysph
agia
√
147 Shaloni H 28157 55/M 800 wt-69kg OG   jn Dysph
agia
148 Rajagopal H 38788 55/F 800 M DIFFUSE √ √ √
149 Selvaraj H 51535 65/M 800 √ √ M ANTRUM √ √
150 Marammal H 44086 65/F 800 M PYLORIC √ √
133 √ √ √ √ AB+ve Ascites + Growth Body Adeno CA Growth Body Ascites
134 √ √ √ B+ve N AntralGrowth Growth antrum
135 √ √ A+ve N Growth Body Adeno CA Growth Body LN
136 √ √ √ B+ve Antral wall thickening AntralGrowth Adeno CA
Growth Antral Ascites 
Post. INFIL.
137 √ O+ve Antral wall thickening AntralGrowth Antral Growth LN
138 √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
139 √ B+ve Antral wall thickening AntralGrowth Adeno CA Antral Growth
140 √ √ O+ve Antral wall thickening Ascites
Antral
Growth Adeno CA
Antral Growth Ascites 
2° Liver
141 A+ve Antral wall thickening AntralGrowth Adeno CA
Antral Growth Ascites 
2° Liver
142 A+ve N Cardia Growth Adeno CA Cardia Growth
143 AB+ve Ascites Cardia Growth Adeno CA Growth Cardia Liver 2° Ascites
144 B+ve - Growth OG JN Adeno CA Oesophageal infilt.
145 O+ve N Cardia and Fundus
Growth Cardia and 
Fundus
146 O+ve Liver 2° OG JN Adeno CA Growth OG JN Ascites Liver 2°
147 B+ve N OG JN Poorly DiffAdeno CA
Growth OG JN 
Ascites Liver 2°
148 O+ve Ascites Growth Body Poorly DiffAdeno CA Diffuse involvement
149 A+ve Antral Growth AntralGrowth Adeno CA
Growth Antrum Liver 
150 A+ve Antral Growth AntralGrowth
Poorly Diff
Adeno CA
Growth Antrum Liver 
CA STOMACH PROFORMA
  
Name :
Age :
Sex :
Ip no :
DOA :
DOS :
DOD :
Unit :
Complaints
Mass abdomen    : duration
                           Size
                               Site
 
Pain abdomen     : duration 
                               location
                               nature-  colicky / dullaching /others
Jaundice       : duration
                               obstructive/hepatocellular
Vomiting       : nature   food/bile/blood/others 
Fever
H/o dyspepsia
H/o ball roling movements
Abdominal distension
H/o pruritis
bowel habits – constipation/diahorrea/melena/steatorrhea
H/o drug intake
Past history
DM/HT/TB/BA/IHD
H/O previous surgery
H/o jaundice
H/o blood transfusion
Personal history
Diet;  veg/non veg/mixed/ fatty meals/smoked food
smoker / alcoholic
Menstrual history
Treatment history
General examination
Nutrition
Hydration status
Anaemia.
Jaundice.
Pedal edema.
Lymph nodes.
Vitals-PR :   BP :     RR :     TEMP :
SYSTEMIC EXAMINATION:
PER ABDOMEN :
INSPECTION :
Site :
Size :
Shape :
Umbilicus :
Veins/pulsation
Moves with respiration.
PALPATION:
Consistency
Warmth tederness
Guarding/rigidity
Organomegaly
PERCUSSION:
Liver dullness
Over the mass
Free fluid
Shifting dullness
Fluid thrill
AUSCULTATION
Bowel sounds
DRE
OTHER SYSTEMS - CVS/RS/CNS/LOCOMOTOR
CLINICAL DIAGNOSIS
INVESTIGATIONS
HB%
TC
DC 
ESR
URINE - alb/sug /dep
BLOOD - sug/urea/creatinine
SR - electrolytes-na,k
LFT  -    sr.bilurubin
             SGOT/AST
              SGPT/ALT
              Sr.proteins  - alb/glo/total
X RAY CHEST PA VIEW
XRAY ABDOMEN     - supine/ erect
Endoscopy      - upper gi endoscopy
HPE Report
H.PYLORI
OPERATION NOTES
POST OP FOLLOW UP
Day of ryles tube removal
Day of suture removal
Complications
Period of follow up  -  RT/CT
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INTRODUCTION
Carcinoma stomach is one of the leading causes of morbidity and mortality accounting 
for 12% of deaths. There has been a decline in its incidence since 1930. Even though the 
incidence of distal gastric  cancer is decreasing  in  western countries,  incidence of proximal 
gastric cancers continue to increase.
 The  overall 5-year  survival  rates  ranging  from  53%   in  Japan  to 10%  in  Eastern 
Europe.A better outcome is obtained in Japan due to an active screening programme resulting 
in  earlier  diagnosis  and  an  aggressive   surgical  approach. The    combination    of 
chemoradiation  therapy  and  curative  resection increases   disease  free  and  overall  survival 
duration    which      has  led  to   recommend  multimodality treatment   in    patient  with 
systemic   disease.  Inspite   of    this  multimodality  treatment  the  morbidity  and  mortality 
continues to be  high.
AIMS OF THE STUDY
This study was mainly to  analyse cases of carcinoma  stomach in our region which 
commonly  present to  the  general  surgeon  in the  department of  general surgery , Tirunelveli 
medical college hospital, Tirunelveli.
The study was conducted in the following principles.
• To study the anatomical location of growth with respect to age and  gender  distribution
• To study the Etiology & Risk factors with respect to anatomical location.
• Study of H.Pylori  association  with  carcinoma  stomach.
• To study the sensitivity and specificity of various investigation modalities used.
• To study the Histopathological variety in relation to the site of growth
• To study the mortality and morbidity rate with reference to treatment modality.
MATERIALS AND METHODS
           This study was conducted in the general surgery department , Tirunelveli  medical 
college  hospital ,Tirunelveli  for  a  period of  30  months,  from June  2006  to  November 
2008.
• 150 Cases of Carcinoma stomach were studied during this period.
• Details of 150 patients with Adenocarcinoma were retrieved and follow up of these 
patients was done with the surgical treatment modalities used and its outcome and 
survival.
• Cancer recurrence after surgery and cancers after GJ for peptic ulcer disease were 
excluded from this study. 
• Age,  gender,  predisposing  factors,  clinical  presentation  and  surgical  treatment 
modalities used were recorded in a prestructured  proforma. 
• The site of the stomach tumours was recognized as involving one of the four sites. 
Namely 
1. OG Junction 2. Proximal Stomach (Cardia & Fundus)
3.  Body    4. Antrum
• Only those cases which received some form of  surgical  treatment were  included  in 
the  study.
• Association of H.Pylori with gastric cancer study was carried out in eleven patients 
of  histologically  proved  gastric  carcinoma.
• The WHO classification of HPE report was combined with Lauren’s HPE  type in 
order  to  study  the  Histopalthology  type in  relation  to  tumour location.

DATA ANALYSIS
• The Commonest abdominal malignancy in our region is CA stomach.
• The Common site of involvement in CA stomach is Pyloric Antrum  constituting  117 
out  of  150  cases.
• This was in concordence with the study of cherian et al (2007), Sivaraman et al.
• This study, is contradictory to the rising incidence of AdenoCA of proximal  growth 
in  the  West,  Iran,  Sweden &  Kerala
SITE DISTRIBUTION
Site No of cases % 1993,TVMCH
OG jn 6 4% 2%
cardia 7 4.6% 2%
Body 15 10% 24%
pylorus 117 78% 48%
Linitisplastica 5 3.3% 10%
• Proximal  growth shows an increase of  2%  when compared  to the  previous  study.
• A  decline in  the incidence  of  body growth (10%) was  found   in  this  study.
• Antral  growth  continues to increase   by   30%   in  this  study.
• The study revealed that the distal  growth  is continue to be increasing  our  region   than 
the    proximal  growth .
AGE   DISTRIBUTION
Site Age   groups<30 30-39 40-49 50-59 >60
OG  jn 2 2 2
Cardia 2 3 2
Body 2 7 2 4
antrum 1 8 16 34 52
Linitisplastica 3 2
• The age group  affected  is evenly distributed   in cancers involving  OG   jn above 40 
years..
• Significant  increase  in  the  number  of patients  after the  age  of 50  years  was  seen 
in  cancers  involving  pyloric  antrum.
• Both the youngest age(24yrs) at presentation and oldest age(84yrs) of presentation were 
seen in Antral growth.
• This  is  concordance  with  the  results  of  Lee  et  al  and  Kim  et al.
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SITE DISTRIBUTION
AGE   DISTRIBUTION
GENDER DISTRIBUTION
Site Male Female Ratio
OG jn 3 3 1
Cardia and fundus 6 1 6
Body 11 4 1.2
Pyloric antrum 96 20 4.6
Linitis plastica 3 2 1.5
• The male : female ratio of cancers involving the proximal stomach, body, antrum and 
OG Jn was 6, 1.2, 4.6 and 1 respectively.
• This was not in  concardance with the study of Cherian et al, where  the ratio is 3, 2, 3 
and 4 respectively.
MEAN AGE  DISTRIBUTION
Site Male Female SJE 2007Male
SJE 2007
Female
OG jn 47.5 47 50.5 46.25
Cardia&fundus 51.4 45 55.47 50
Body 52.5 58.1 55.43 46.37
Antrum 56.7 60.1 55.5 52.86
Linitis plastica 51.3 57.5 - -
• Mean Age of  occurrence  is low  in  both  sexes  having  proximal    growths.
• This  is  in concardance with the study of  Saudi gastroenterology  2007.
ETIOLOGICAL ASSOCIATION
Site Smoking Alchohol
Smoked, 
spicy 
foods
Blood Grouping
A B AB O
Fatty 
food
OG  jn 3 1 2 2 3 0 1 6
Cardia&fundus 3 1 1 3 0 2 1 7
Body 3 2 12 2 3 4 6 5
Antrum 62 48 78 39 39 12 27 15
Linitis plastica 3 1 2 2 0 0 3 1
• Smoking contributes 100% association of cancers in OG Jn in males  and 71.4% in 
cardia  and  64.58%  in  Antral  growth.
• Gammon et al,  Inoue et al describes the association between smoking and  proximal 
gastric cancers.
• Blood   group A   is the  most common group  affected by Carcinoma Stomach in our 
region. AIRD describes the association between ca stomach and Blood group A.
• Smoked and spicy food shows an increased association with antral growth.
• Fatty food  has  an  increased  association  with   proximal  cancers.
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H.PYLORI  STUDY
• 11  Patients   underwent  study  of  H.pylori  by  subjecting  them  to  ELISA   of   IgG 
Antibody of   H.Pylori  kit
• About 5ml of blood was drawn from each patient,serum  was  separated  and    the  IgG 
Antibodies  were  measured.
• The results  were interpreted  as positive if the value is above 20IU  and  negative  if  it 
is  below  20IU.
• One  patient with OG jn  growth ,two patients with body of growth, eight  patients with 
pyloric antral growth  were subjected to study.
• The study includes  seven patients  of more than 60 years  of age, two  patients  of   fifty 
to  sixty  years  of  age, one  patient  below 50  years  of  age  and  one  patient  of  thirty 
five  years  of  age.
• Of  these six patients are with  blood group A,  eight  patients with intestinal type  of 
lauren’s  classification, one patient with mucinous Adenocarcinoma and two patients 
with  poorly differentiated  Adenocarcinoma.
           From  this  study ,the  following  results  were  obtained
• H. Pylori showed  an association  with   intestinal  type  of   86.5%
• This  is   in   concordance  with  study  of   Anderson et al  of 90% 
• Age  group  affected  in  H.pylori infection   is  above  60 yrs.
• This  study  corelates  well   with study   of Feilding  et al &  Hunt et  al, shows an 
association  of age group affected above  60 yrs.
• H. Pylori  shows an  association with antral growth in 27.2% of patients and body of  the 
stomach  in  18%  of   patients
• Sibata  et  al shows an association of 68% with antral growth  50%  with  cardia  growth 
and  66%  with  body  of  growth.
• H.Pylori  shows an   50%  Association   with   BLOOD  Group A.
SENSITIVITY & SPECIFICITY OF INVESTIGATIONS
Site Endoscopy USG BA meal Ba swallow
OG jn 96% 0% - 42.8%
Cardia&fundus 100% 0% -
Body 100% 20% - -
antrum 96.39% 90% - -
Linitis plastica 20% 40% 100% -
• Endoscopy  was  done  for  140 cases
• Endoscopy and Biopsy shows 96.39% in detecting Antral growth  and  100%  in 
detecting  Cardia &  Body  growth  and 96%  in  detecting  growth  in  OG Jn.
• USG has a sensitivity in detecting  Antral growth as Antral wall  thickening in  90% 
of  cases.
• Ba meal has a sensitivity of 100% in detecting Linitis   Plastica.
HISTOPATHOLOGY ASSOCIATION
Site Intestinal type
Diffuse 
type Mixed
Chandha, khan et al
2007
Intestinal 
type
Diffuse 
type
Mixed 
type
OG jn 2( 33.3%) 4(66.6%) - - - -
Cardia & 
fundus
2(28.5) 3(66.6%) 2 5.3% 15.3% -
Body 11(73.3%) 4(2.6%) - 8% 15.3% 4%
96%
100%
100%
96.39%
20%
OG jn Cardia&fundus Body antrum Linitis plastica
Antrum 107 
(91.45%)
7(5.9%) 3 28% 27.3% 8%
Linitis plastica - 5(100%) - - - -
• The Intestinal type of Lauren’s classification is found in 91.45% of cases of Antral Growth.
• The diffuse type contributes to 5.9%    in  growth  of     Antral cancers.
• The mixed type  contributes  1%  in  Antral  growth.
• The diffuse type is predominantly seen in proximal cancers and Linitis Plastica contributing 
66.6%.
ENDOSCOPY
INTESTINAL TYPE
28.5
73.30% 83.76% 0 33.30%
OG jn Cardia & fundus Body Antrum Linitis plastica

Chandha et al and  khan et al  in 2007  describes   intestinal type is more common in the 
pyloric antrum and  cardia and fundus growth shows a predominance of  diffuse  type.
STAGING
Stage No of patients %
Stage 1a - -
Stage 1b - -
Stage 2 10 6.6%
Stage3a 11 7.3%
Stage3b 3 2%
Stage 4 126 84%
Site Stage1a
Stage
1b Stage2 Stage3a Stage3b Stage4
OGjn 1 5(83.3%)
Cardia 1 1 5
Body 2 1 1 11
Antrum 6 9 2 100(66.6%
)
Linitis 5(100%)
• The proximal tumours are usually advanced at presentation and  have poorer long term 
prognosis  -anderson et al
• In  this  study  OG  jn  growth   shows   of  83.3%  STAGE  4  disease
&pyloric antrum shows 66.6% of   STAGE 4 disease
NODAL STAGING
Staging No of patients %
No 28 18.6%
N1 94 62.6%
N2 20 13.3%
N3 1 0.6%
M STAGING
Staging No of patients %
M0 24 16%
M1 16 10.6%
STAGING
0 0
6.60% 7.30%
2%
84%
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SURGICAL RESULTS
Surgery No of cases Morbidity Mortality Mortality
Total gastrectomy 8 12.5% 37.5% 8%
Sub total gastrectomy 8 - - 10%
Distal gastrectomy 10 - -
Distal gastrectomy and
Roux en y
3 - - -
Palliative    distal 
gastrectomy
44 - 2.8% 7%
Anteriorgastrojejunostomy 63 1.3% 9.5% -
Feeding jejunostomy 14 - 2.8% -
• Total gastrectomy was done for eight patients with a morbidity rate in  two  cases 
and  mortality  of  three cases.
• The palliative procedure shows high morbidity may be due to  disease  process  in 
my   study.
• Anastomotic  leak  was  found  in  six   patients  with   4%.
• .The most devastating complication is anastomatic leak in 3%-21% of cases - 
anderson et al
• Death  due  to  co  morbid illness  in  4%  of  patients.
• Sub total gastrectomy and curative  distal gastrectomy did not show any mortality in 
my study.
REVIEW OF LITERATURE
Carcinoma stomach is the one of the leading cause of cancer related death in world 
wide. It is the  eighth most common cancer in US. It is the seventh  most common cancer In 
India.  There has been decline in its incidence since 1930. Although the incidence of distal 
gastric cancer is decreasing in the world, the incidence of proximal gastric tumors continues to 
increase.
The approximate incidence of gastric carcinoma in the United States is 10cases/1,00,000 
people. In Japan -78 Cases/1,00,000 people. In India, cancer stomach is the 6th common cancer 
in male and 7th most common cancer in female.In TVMCH the incidence of ca stomach is 
8.79% based on cancer registry  during the period 2001-2002. In particular, gastric cardiac 
tumors are five times more common and non-cardia gastric tumors are twice as common in 
men  as  women.  The  incidence  is  also  higher  in  low  socio  economic  populations  of 
developing countries. Survival rates in patients with gastric cancer is poor. The overall 5-year 
survival rates ranging from 53%  in  Japan  to 10% in Eastern Europe. The analysis of the 
national cancer Data base of US revealed 6% to 12% better 5 year survival rate for women 
than for  men, for patients with distal  as opposed to proximal tumours.  continues to be high.
HISTORY
 Billroth, Wölfler 1881    First  successful resection on human patient
Wölfler,nicolondi 1881    Performed antecolic gastrojejunostomy 
Braun 1893    Described jejunojejunostomy as routine 
                                               addition  to gastrojejunostomy
 Billroth,          1874    Billroth I - Distal gastric resection with
                                               anastomosis of Stomach and  duodenum. Billroth II - 
Anastomosis of stomach with  jejunum 
                                                through    transverse mesocolon
ANATOMY  OF STOMACH.
For descriptive purposes ,the stomach is divided into
Lesser curvature
This continue  with  the  right  free border esophagus and forms the  concave border of 
the stomach.
Greater curvature
This starts at the cardiac notch  and forms the convex  border of the  stomach.
The fundus
This is the area above the horizontal line from the cardiac  notch to the greater curvature 
of the stomach.
The incisura angularis
In a J shaped stomach this is the junction of vertical and  horizontal  parts of the lesser 
curvature
The body
This is the portion of stomach  lying  between   the fundus and  pyloric portion of 
stomach.
The pyloric portion
The distal one fifth of the stomach consists of pyloric antrum ,canal and  sphincter .The 
pyloro duodenal junction is identified by the vein  of mayo.
SURGICAL ANATOMY OF STOMACH 
SKANDALAKIS ET AL  divide the stomach into proximal gastric unit 
and distal gastric unit.
Proximal gastric unit consists of
Distal esophagus   -  0.5 -2.5cm
Og jn and esophageal hiatus
ANATOMY OF STOMACH
                         BLOOD   SUPPLY OF STOMACH
Proximal stomach(cardia &fundus)
Distal gastric unit consists of
Gastric antrum
Pylorus 
1st  part  of  duodenum  -first  2.5  cm of  duodenum 
Relations of  proximal  gastric  unit 
Lesser & greater curvature
The upper part of lesser sac
OG  jn
Lesser curvature of body, GE jn  and  the  abdominal  esophagus  are attached to the hepato 
gastric ligament and  its  contents .The greater curvature attaches to the upper part of greater 
omentum and several related  splenic  ligaments.like  gastrosplenic and splenoleinal  ligament. 
Relations of distal gastric unit
The lesser curvature of  antrum, pylorus and  upper part of duodenum are attached to 
hepatogastric  and  hepato duodenal  ligament
The greater curvature is attached to gastrocolic ligament.
Posterior relations  of  distal gastric unit
• Floor of lesser sac
• Transverse mesocolon
• head  &  neck of pancreas
• Aorta&celiac trunk & branches
• Celiac ganglion & plexus
• Hepatic triad
• Gastro duodenal artery
Anterior relations  of distal gastric  unit
• Anterior abdominal  wall
• Medial  segment  of  left  lobe  and  anterior  segment  of  right lobe  of liver
• Transverse mesocolon
• Neck of gall bladder
BLOOD SUPPLY OF STOMACH
The four main arteries of stomach are
LEFT GASTRIC ARTERY
Arises from coeliac axis The left gastric artery commonly divides into an anterior and a 
posterior branch before attaining the lesser curvature111 and, in such cases, the esophageal and 
cardioesophageal arteries may arise, variably, from either of those vessels; more commonly, 
however, the cardioesophageal artery arises from the anterior gastric branch. 
After its cardioesophageal branch the left gastric artery usually curves downward to the 
right and thereafter descends along the lesser curvature. As it descends, it bifurcates into an 
anterior branch which sends branches to the anterior gastric wall, and a posterior branch which, 
similarly, supplies the posterior gastric wall. A smaller continuation of the left gastric artery 
continued along the lesser curvature.
RIGHT  GASTRIC  ARTERY
The right gastric artery  is a small branch which arises most commonly from the proper 
hepatic artery (50-68%), left hepatic artery (28.8-40.5%), common hepatic (3.2%), The right 
gastric  artery  gives  origin  to  one  or  more  suprapyloric  branches.  Anterior  and  posterior 
branches from these anastomose with infrapyloric vessels and with the supraduodenal artery, 
providing for the distal gastric unit (antrum, pyloric canal, first inch (2.54 cm) of the first part 
of the duodenum). The right gastric passes along the lesser curvature for about 4 to 6 cm, about 
0.5 cm from the lesser curvature, before anastomosing with the left gastric. In about 13% of 
individuals, the right gastric artery provides origin for the supraduodenal artery.
RIGHT  GASTRO EPIPLOIC ARTERY
The  right  gastroepiploic  artery   is  a  branch  of  the  gastroduodenal  artery  (or  its 
continuation) in most cases. It occasionally arises from the superior mesenteric artery or from 
the anterior superior pancreaticoduodenal artery. After giving origin to an infrapyloric branch, 
the  artery  passes  along  the  greater  curvature  of  the  distal  gastric  surgical  unit  within  the 
gastrocolic ligament. It gives origin to 8-18 singular or paired anterior and posterior branches 
for  the  gastric  wall.  The  gastric  branches  of  the  right  gastroepiploic  artery  pass  mostly 
undivided in a submucosal position about one-fifth of the distance from the greater curvature. 
They  anastomose  extensively  with  branches  from  the  left  gastric  artery.108 If  the  first 
infrapyloric branch is particularly large, the first following gastric branch tends to take its origin 
further around the greater curvature. In about 75% of individuals, the right gastroepiploic artery 
clearly anastomoses with the left gastroepiploic,111 although not so profusely as is seen in the 
anastomoses with the left gastric artery. 
The gastroduodenal artery ran in front of the common bile duct and descended along the 
posterior surface of the head of the pancreas 
LEFT GASTRO EPIPLOIC ARTERY
The left gastroepiploic artery is the largest branch of the splenic artery.56 It reaches the 
stomach at a point about halfway along the greater curvature,  after it  has already delivered 
several rather long branches to the more proximal part of the greater curvature. These branches 
reach the stomach by way of the gastrosplenic ligament.The left gastroepiploic artery gives off 
the  left  epiploic  and  the  anterior  epiploics.  Together  with  similar  branches  of  the  right 
gastroepiploic, they form the arc of Barkow , which is reinforced also by the posterior epiploic 
branches of the inferior pancreatic artery . 
VEINS OF THE STOMACH:
The veins of the stomach  mainly accompany the arteries. Of particular importance  is 
the left gastric or coronary vein,receives branches  from the esophagus.
LYMPHATIC SUPPLY OF STOMACH
The lymph nodes concerned in the drainage of stomach are.
HEPATIC GROUP
 Lymph nodes lie in the lesser omentum along the bile ducts  and receive lymph from 
the liver and gall bladder.
SUB PYLORIC GROUP
Lie in  the  angle  between  first  and  2nd   parts  of  duodenum on the head of pancreas 
in relation to duodenal artery.Receive the lymph from right  two  thirds  of  greater  curvature 
of  stomach.
GASTRIC GROUP
Superior nodes    - lie  along  left  gastric  artery  and  para  cardial nodes
Inferior  nodes     - lie  along  the  pyloric  half  of  greater  curvature  of 
 the  stomach
PANCREATICOLIENAL GROUP
These  lie  along  the  splenic artery in relation to upper border of pancreas.
JAPANESE CLASSIFICATION OF LYMPH NODES
1. Rt. Paracardial
2. Lt Paracardial
3. Along Lesser Curve
4. Along Greater Curve
5. Suprapyloric
6. Subpyloric
7. Lt Gastric
8. Common HepaticCoeliac Axis
9.  Splenic Hilum
10.  Splenic Artery
11.  Hepatoduodenal Ligament
12.  Retropancreatic
13.  Superior mesentric
LYMPHATIC SUPPLY OF STOMACH
JAPANESE CLASSIFICATION OF  LYMPHATIC SUPPLY OF STOMACH
14.  Middle colic
15.  Para aortic
16. Anterior pancreatic
17.  Inferior pancreatic
18.  Infra diaphragmatic
19.  Oesophagial Hiatus
20.  Lower Paraoesophageal
21.  Supra diaphragmatic
The gastric wall consists of the serosa, the muscular layer, the submucosal layer, and the 
mucosal layer. 
SEROSAL LAYER
The serosa is nothing more than the peritoneum, a thin layer of loose connective tissue 
underlying a layer of simple squamous mesothelium.
MUSCULAR LAYER 
The  anatomist  describes  the  three  well-known  layers  of  musculature:  an  outer 
longitudinal  layer,  middle  circular  layer,  and  inner  oblique  The  outer  longitudinal  layer  of 
muscle is present along the lesser and greater curvatures Its fibers are arranged into two groups. 
The first set is continuous with the outer smooth muscle layer of the esophagus. The fibers are 
best developed along the curvatures,  ending proximal to the pyloric region. The second set 
begins in the body and passes to the right, with the fibers becoming thicker as they near the 
pylorus. 
The  middle  circular  layer  rather  uniformly  encircles  the  entire  stomach  and  "is  the 
principal part of the muscular coat," according to Woodburne.55 This layer becomes thicker at 
the pylorus, most distally forming the pyloric sphincter .
The inner oblique muscle layer, internal to the circular layer, is limited to the body of the 
stomach and is most developed near the cardiac orifice.
SUBMUCOSAL LAYER
The  submucosa  is  composed of  loose,  areolar  connective  tissue  which  connects  the 
mucosa to the external  musculature.  It  can be called the "vascular layer" (both arterial  and 
venous) of the gastric wall. It houses plexuses that have rich anastomoses through extensive 
ramifications that form excellent collateral flow. All the parts of the gastric mucosa receive 
blood from th ese   submucosal plexuses except the lesser curvature.
 MUCOSAL LAYER
• The distal esophagus is lined by stratified squamous epithelium, with mucous cells in the 
abdominal esophagus
• The cardia contains simple columnar cells
GASTRIC MUCOSA SURFACE
• The fundus and body contain two types of cells: parietal (oxyntic) acid-secreting cells 
and chief pepsin-secreting cells
• The lamina propria of the fundus and body is filled with branched, tubular gastric glands
RISK FACTOR 
HELICOBACTER . PYLORI
Sibata et al & Huang et al found H.Pylori positivity is more associated with non-cardia 
gastric  cancer. H.plyori  was  detected  in 90% of  intestinal type of cancer &32% of diffuse 
type  cancer. It is also as associated with  MALT and gastric Lymphoma. H.Pylori increases the 
risk of gastric cancer  by impairing the  bioavailability of vitamin C.
WARREN, in 1980  detected a curved s shaped bacilli in light microscopy. Initially it 
was  recognized  as  campylobacter  jejuni.in  October  1989,  the  organisms  was  named 
helicobacter, because of the presence of sheathed flegelle,a unique fatty acid profile, different 
repiratory quionones.The isolation of H.Pylori from the gastric mucosa and the report of the 
organisms urease activity  was postulated by MARSHALL.
H. Pylori is almost  associated with  inflammatory response.The spiral shaped organisms 
allows efficient motility in the mucus and in the gastric juice. The enzyme urease by breaking 
down  urea in the gastric juice  appears to generate enough bicarbonate and ammonium  ions 
around the organisms to allow its safe passage  through the  gastric acid barrier  to reach the 
mucous layer.Ammonia  elevates the pH of the gastric mucosa  from about  6-7.It is known to 
deplete  aerobic cells of  alpha keto glutarate, an essential substrate  for the TCA   acid cycle. 
Once attached to the mucus layer and the mucosa, H.Pylori,  secretes soluble proteases and 
phospolipase, which may be harmful to the mucus layer.
The vacuolating cytotoxin is a 87  kda  protein  , expressed in about   65%  of  H.Pylori 
strains and is responsible for creating vacuoles   in the epithelial cells. The gene for cytotoxin 
protein is  V ac A. The  Vac  gene is present in all H.Pylori bacteria but only produces an 
active protein in 65% of isolates.A second protein at 127 kda is called  cytotoxin associated 
gene and is called Cag  A   gene. Cag  A   gene is a marker   for vacuolating  cytotoxin effect 
and is only present  when Vac A cytotoxin is present. The organisms have been classified into 
Type І  0rganisms which have  Cag  A  and Vac A which are more ulcerogenic and type ІІ 
organisms that lack Cag A and do not produce cytotoxins.  H. Pylori infection is associated 
with  increase gastrin levels and decrease somatostatin levels, which has led to the development 
of atrophic gastritis  ,a precancerous condition of  gastric carcinoma.  Epidemiological studies 
have  demonstrate  that  there  is   an  association  of   H.Pylori  with  gastric  carcinoma  .  this 
infection has three fold to six fold higher risk for developing  gastric cancer than those without 
infection.                  
The incidence of gastric carcinoma  tends to be high in geographic regions  were  people 
consumes  diets  high  in  salt & smoked  foods. The presence of nitrosamines  in the smoked 
food is a carcinogen in developing the carcinoma.
Smoking has a five-fold increased risk of   cardia and upper-third gastric cancer and   a 
two-fold     increased  risk  of  distal  gastric  cancer  compared to   nonusers.
Male  gender,  Black  race  &  low  socio  economic  class  are  associated  with  Gastric 
carcinoma.
                Obesity is  associated with Proximal gastric cancer.
                Occupational hazard exists for metal workers is a associated factor for distal gastric 
cancer.. 
               An associate  between  gastric carcinoma and  blood   group  A was  described  in 
1953  by…AIRD ET AL….
PREDISPOSING FACTORS
Gastric  polyps particularly  Villous   Adenomas   indicate   increased   risk   of 
malignancy.
Pernicious Anemia is  associated  with  10%  incidence  of  gastric cancer. 
 Mutations  in  CDH1…. Gene  that  encodes  E. Cadherin   is more  common  in 
diffuse   type   gastric   cancer.  Mutations  in  the  CDH1 gene  that  encodes  E-cadherin,  an 
epithelial cell adhesion molecule, may be found in intestinal cancers but are more common in 
diffuse-type gastric cancers. Furthermore, defects in E-cadherin  mediated cell adhesion are 
characteristic of diffuse-type gastric tumors. It also appears that a CDH1 gene mutation occurs 
in  a  cluster  of  patients  with  hereditary  diffuse  gastric  cancer.  Therefore,  prophylactic 
gastrectomy is offered to carriers of these mutations. Virtually all carriers of this mutation so 
far have been found to harbor an early malignancy in the resected specimen, despite negative 
initial endoscopy findings, pointing to the advisability of the gastrectomy.
Vascular endothelial growth factor C (VEGF-C) is a glycoprotein that belongs to the 
VEGF family. VEGFs are cytokines that play an important role in angiogenesis.    In gastric 
adenocarcinomas, expression of VEGF-C mRNA is associated with lymphatic invasion, lymph 
node metastasis, and possibly a less favorable outcome
P53  over  expression revealed  in  more  than  55% of tumors.
Previous  partial gastrectomy  &  Menetrier’s disease –  Pre disposing  factor for  gastric 
cancer.
Hypogammaglobulinaemia  is  associated  with   gastric  cancer.
PATHOLOGY
Approximately   10% of these  tumours    are polypoid fungating  tumours, with  a 
relatively    good    prognosis   after  aggressive  surgical   management. Ulcerating  or 
penetrating cancers,  which   occur in more than  50% 0f patients, are sessile.  Superficial 
spreading carcinoma  is more unusual( 6% of tumours). This tumour is diffusely  infiltrative 
over a wide area,although it is predominantly  confined to mucosa  and submucosa. A further 
subgroup  of   diffusely   infiltrative   cancer   is  the  LINITIS   PLASTICA (leather  bottle) 
carcinoma  and carries particularly  poor prognosis.
EARLY GASTRIC CANCER
           The  term  early gastric cancer describes   tumours  confined  to the   gastric mucosa 
and  submucosa, irrespective  of  nodal  status. Based on endoscopic appearance,( JAPANESE 
CLASSIFICATION),it is divided into three groups,type-1 protruding ,type -2 superficial ,and 
type-3  –  excavated.  Type  -2  is  divided  into   three  subgroups,a)  elevated   b)  flat  and 
c)depressed Early gastric cancer accounts  for 40%  of  all gastric cancers in Japan.  In the 
west,early gastric cancer accounts for 9% of all  cancers detected.50% of cases  progress to 
advanced  cancer within three years from the time of endoscopic  diagnosis, and almost all 
patients develop  advanced disease within five years.
CA STOMACH WITH ASCITES
   METASTATIC CUTANEOUS  NODULES IN  CA STOMACH 
ADVANCED GASTRIC CANCER
Advanced  gastric  cancer  suggests  invasion of  the  muscularis  mucosa or  beyond.  It 
shows  serosal  involvement,  invasion  of  adjacent  organs,extensive  nodal  metastasis  and 
secondary deposits usually within the peritoneal cavity.By, definition these tumours always 
exceed two cm in diameter    (.BORRMANS CLASSIFICATION)
MICROSCOPIC APPEARANCE
The great majority of gastric cancers are Adenocarcinoma; other tumours are rare.
WHO CLASSIFICATION
The   WHO  classification based on morphology  divides gastric cancers  are  into five 
types:adeno carcinoma,adenosquamous carcinoma, squamous cell carcinoma, undifferentiated 
carcinoma, and unclassified carcinoma.   Adenocarcinomas contribute 95% of gastric cancers 
which arises from the mucous producing rather than acid producing cells of gastric mucosa 
The adeno carcinoma  are divided into  four patterns; papillary, tubular, mucinous, and  signet 
ring, which  may be divided by  degrees of differentiation. In tumours presenting a mixed 
picture  with  varying  degrees   of  differentiation  in  the  same  tumour  ,is  based  on  the 
predominant type.
Lymphomas , carcinoid, Leiomyosarcoma,  GIST  of stomach , adenosquanmous and 
squamous cell carcinoma comprise 5% of gastric cancers. 
LAUREN’S CLASSIFICATION:
According to Lauren’s classification, the two  Histologic  types of gastric carcinoma are 
intestinal and diffuse. The intertinal type have the tendency of Malignant cells to form glands. 
The diffuse type lacks organized gland formation, ie usually poorly differentiated and has many 
signet ring cells.The  intestinal  type  carries  the the more favorable prognosis and  is  more 
common in areas with a high incidence  of  the  disease.
MING CLASSIFICATION
    In this classification ,cancers were divided into  an  expanding  type that  produces  nodules 
that compress  adjacent  tissue (Laurens intetinal type), and the infiltrative  type  that does not 
forms masses( Lauren’s diffuse type)
CLINICAL PRESENTATION
Gastric adenocarcinoma is usually not associated with specific symptoms early in the 
course of the disease. Patients often ignore the vague epigastric discomfort and indigestion that 
portend the cancer and may be treated presumptively for benign disease for 6 to 12 months 
before diagnostic studies are performed. Rapid weight loss, anorexia, and vomiting are usually 
a sign of advanced disease.  These presenting features are simply due to the presence of a 
partially obstructing lesion .
            The epigastric pain is usually similar to the pain caused by benign ulcers and is often 
relieved by eating food; however, it can mimic angina. Dysphagia is usually associated with 
tumors  of  the  cardia  or  gastroesophageal  junction.  Antral  tumors  may cause  symptoms of 
gastric outlet obstruction. Although very rare, large tumors that directly invade the transverse 
colon may present with colonic obstruction. Physical examination will reveal a palpable mass 
in up to 30% of patients.
          
Signs of Metastasis disease is found in 10% of patients.
The most common indications of distant metastasis are a palpable supraclavicular  lymph 
node  (Virchow  node),  a  mass  palpable  on  rectal  examination  (Blumer  shelf),  a  palpable 
periumbilical  mass (Sister Mary Joseph node),  ascites,  jaundice,  or a  liver mass.  The most 
common site of hematogenous spread is the liver; tumor also frequently spreads directly  to the 
lining of the peritoneal cavity
 Gastric  tumors  may  be  associated  with  chronic  blood  loss,  but  massive  upper 
gastrointestinal bleeding is rare. In Japan, the high incidence of gastric cancer has led to routine 
endoscopic  screening;  as  a  result,  in  that  country,  more  than  50% of  gastric  cancers  are 
diagnosed at an early stage.
STAGING SYSTEM
           The  Pathologic  staging  system  currently  in  use   worldwide  is  the  American  joint 
committee  on  cancer  TNM  staging  system  with  the  addition of the term R status to denote 
residual  disease  remaining  after  resection
TNM STAGING
The   American  joint  committee  on cancer (AJCC)  has  designated staging by TNM 
classification.
PRIMARY TUMOUR
• Tx  : Primary tumour cannot be assessed
• T0:  no evidence of primary tumour
• Tis: carcinoma in situ: intra epithelial tumour without invasion of the lamina propria
• T1:Tumour invades lamina propria or submucosa
• T2:Tumour invades the muscularis propria or the submucosa
1. T2a:Tumour invades muscularis propria
2. T2b:Tumour invades subserosa
• T3:  Tumour  penetrates  the  serosa(visceral  peritoneum)  without  invading  adjacent 
structures
• T4: Tumour invades adjacent structures.
REGIONAL LYMPH NODES
• Nx:  Regional   lymph nodes cannot  be assessed
• N0:  No regional lymph node metastasis
• N1:Metastasis in   1-6 regional lymph  nodes
• N2:Metastasis in  7-15 regional lymph nodes
• N3:Metastasis in  more than 15  regional  lymph  nodes.
DISTANT METASTASIS
• Mx:Distant metastasis cannot be assessed
• M0:No  distant metastasis
• M1:Distant metastasis.
AJCC STAGING
Stage  0      (Tis,N0,M0)
Stage 1a     (T1, NO,MO)
Stage1b      (T1,NI,MO;T2A,N0,M0;T2B,NO,MO)
StageІ І      (T 1,N2,MO;T2A,NI,MO;T2B,N1,M;T3,NO,MO)
StageІІІА  (T2A,N2,MO;T2B,N2,MO;T3,NI,MO;T4,NO,MO)
StageІІІВ  (T3,N2,MO)
StageІV    (T4,N1,MO;  T4,N2,M0; T4,N3,MO; T1,N3,MO;T2,N3,M0;   T3,N3,M0;    Any 
T,ANY  N,M1)  
RESIDUAL DISEASE
R status described by Hermanek and wittekind in 1994 is commonly used to describe the 
tumour status in a patient following resection and is designated following pathologic evaluation 
of resection margins.
R0 -   No residual gross disease and Negative microscopic
               margins.
R1 -    Microscopic residual disease only
          R2        -   Gross residual disease.
INVESTIGATIONS
UPPER  GI  ENDOSCOPY:
Differentiation between benign & malignant gastric  ulcers at endoscopy can be difficult 
and  several  biopsies  are  taken  (ideally  six)  from  all  parts  of  ulcer.  Diagnostic  accuracy 
approaches 100% if 10 samples are taken.
BARIUM MEAL
It gives a better impression of anatomy of tumour, and the degree of obstruction. It is 
also helpful for diagnosis of linitis plastica which may be missed at gastroscopy.
CT SCAN
           
Abdominal and  pelvic CT is performed in the  overall  staging  of patients. CT chest 
may be required for complete staging of proximal gastric tumours. The major limitations of CT 
as  a  staging  tool are in the evaluation of early  gastric tumors and  small  metastases  in  the 
Liver. The  overall   accuracy in determining  tumors  stage  is  66%  to 77%. CT can be used to 
determine nodal stage in 25% to 86% of patients.
ENDO ULTRASOUND
The overall staging accuracy of EUS is 75%. It correctly identifies T2 leisons (38.5%) 
of the time. It is better at identifying T1(80%) and T3(90%) lesions. The accuracy of EUS in 
the nodal evaluation is 65%.
LAPAROSCOPY
          
The Clinical benefit of laparoscopic staging after CT staging is that it identifies  CT 
occult Metastatic  diseases in 23% to 37% of patients.
PERITONEAL CYTOLOGY
Cytologic analysis of peritoneal fluid obtained by peritoneal lavage may identify occult 
carcinomatosis. Patients with positive peritoneal cytology findings have a prognosis similar to 
that of patients with macroscopic visceral (or) peritoneal disease(3 – 9 month median survival)
LYMPHATIC MAPPING:
Gives the essential role of nodal status in gastric cancer staging. Mapping agents such as 
radiocolloid with (or)  without vital dye and activated carbon particles have been used. The 
identification rate varies from 90% from 100%.
POSITRON EMISSION TOMOGRAPHY:
Positron emission tomography, estimate tumour metabolism on the basis of the uptake 
of radiotracer – flurodeoxyglucose – used a staging tool for gastic cancer. This technique may 
reveal CT-occult metastases and may be  used to  assess response to Neoadjuvant therapy.
TUMOUR MARKER
CA 72-4 is  highly specific  to gastric  cancer  and may be more reliable as  a  tumour 
marker than CEA for gastric cancer. Elevated level of CA 72.4 is more frequent than CEA in 
stage III, IV patient  and with  Peritoneal metastasis.
H. PYLORI TESTS.
Tests Sensitivity Specificity
Histology (Geimsa  stain)  93-99%  95-99%
Culture     72-92% 100%
Urease test   89-98% ;     93-98%
Urea breath test                95-98%   95 -98%
Serology  ELISA             88-89%      86-95%
PCR             95% 95%
Stool antigen test               95-99% 90-95
SURGICAL TREATMENT
EARLY GASTRIC CANCER
Endoscopic Submucosal Resection
For mucosal cancers, approximately 3% will be expected to have positive lymph nodes 
and selectively justify the use of an endoscopic submucosal resection (ESMR). Patients with 
submucosal  cancer,  where  the  risk  of  nodal  positivity  can  reach  20%,  would  be  better 
considered  for  limited  laparoscopic  resections  or  limited  open  operations.  Lymph  node 
metastasis  in  both  these  situations  is  associated  with  larger  tumor  size,  undifferentiated 
histology, and the presence of histologic lymphatic or blood vessel invasion. As a working rule 
lymph node metastases are rare if the tumor is less than 2 cm in diameter and well differentiated 
regardless of the depth of mucosal invasion.
Laparoscopic Resection
Laparoscopic  resection  is  being  used  increasingly  for  early-stage  cancer.  This  is 
performed  essentially  by  an  extragastric  approach  after  appropriate  tattooing  of  the  lesion 
endoscopically  so  as  to  ensure  the  ability  to  identify  the  lesion  and  the  adequacy  of  the 
resection. The procedure can be prolonged, and it is essential that clear margins be obtained. 
Progressively more advanced procedures such as distal gastrectomy are being performed with 
the laparoscopic hand-assisted approach using a minilaparotomy
Proximal tumours
 This  tumours  accounts  for  about  50% of  all  gastric  carcinomas.  These  tumours  are 
usually advanced at presentation and associated with poorer  long   term  prognosis.
Siewert classification of OG junction tumours
Type I : Associated with Barrett oesophagus (or) true
esophaged cancer growing into the OG junction
Type II : True junctional  tumours  that lie within 2cm of 
squamo columnar junction.
Type III :   Cancer within subcardial region of stomach. 
Type І : Treatment option for this tumour is oesophageal
resection with 10 cm margin clearance.
Type ІІ : oesophago gastrectomy
Type ІІІ : Total gastrectomy   with reconstruction
          There is no evidence that an extended gastric resection above and beyond complete 
clearance of  the primary tumor improves  survival;  i.e.,  total  gastrectomy does not  improve 
survival over distal or proximal gastrectomy, provided that the tumor is removed completely 
with negative transection margins (R0 resection). The extent of the gastrectomy therefore is site-
dependent and focuses on complete removal of the gastric carcinoma with preferably a 4- to 5-
cm margin  from the  gross  edge  of  the  tumor.  Clearly,  anatomic  limitations  influence  this 
margin because in antral lesions close to or involving the pylorus, only a limited portion of the 
duodenum can be removed. In similar fashion, a lesser extent of uninvolved esophageal margin 
may be acceptable provided complete histologic resection is possible.
Midbody Tumours
These account for 15% to 30% of all gastric cancers.
Treatement  option  for  this  tumours  also  total  gastrectomy  with   regional 
lymphadenectomy.
Distal Tumour
These tumours  account for approximately 35% of all  gastric  cancer.  The standared 
operation for these lesions is distal subtotal gastrectomy with appropriate lymphadenectomy. 
Subtotal gastrectomy entails resection of approximately three  fourths of the stomach, including 
the majority of lesser cuvature.
Extended  organ  resection  is  reserved  for  patients  with  apparently  node-negative  T4 
lesions,  in  which  complete  resection  requires  resection  of  the  invaded  portions  of  the 
diaphragm, pancreas, spleen, adrenal gland.
SURGERY
TOTAL GASTRECTOMY:
( If  the  tumour  involves the  stomach  diffusely or arises  in  the  body of the stomach 
and extends to within 6 cm of the cardia or distal  antrum)    Removal  of  stomach  with 
greater  &  leeser omentum along  with   nodes  en  bloc  with  Roux  en   y   reconstruction. In 
a     total  gastrectomy,  early  mobilization  of  the  left  lateral  segment  of  the   liver  will  be 
necessary to evaluate the extent of a more proximal lesion .However, once the right side of the 
esophagus is isolated, then theesophagus can be encircled, and the left paracardial nodes and 
the  paraesophageal nodes can be reflected inferiorly with the specimen In  this situation, the 
short gastric vessels need to be divided. The left crus is skeletonized, and the left adrenal gland 
is  identified  commonly  ,transect  the  stomach  with  the  placement  of  a  proximal  Satinsky 
vascular clamp, which allows ready stabilization of the esophagus In proximal lesions, a frozen 
section of the esophageal margin is performed. In locally invasive extensive proximal lesions, 
the  mucosal  margin  can  be  benign,  but  extraesophageal  extension  can  be  found  in  the 
periserosal tissues. Once this specimen is removed, the jejunal loop is isolated and divided with 
the GIA stapler .The small intestine for the Roux-en-Y anastomosis is divided with the stapler. 
Attention should be paid to ensure adequate vascularity of the limb, and some require careful 
transillumination to be sure that the arterial arcade is maintained without subsequent tension. 
The  reconstruction  can  be  performed  by  a  direct  end  of  
SUB TOTAL GASTRECTOMY WITH BILLROTH – II - ANASTAMOSIS
       
ROUX EN Y   OESOPHAGO JEJUNOSTOMY
               
esophagus to jejunum anastomosis It is helpful in the sutured anastomosis to place a single 
stabilizing suture in the posterior aspect of the esophagus, suturing the posterior aspect to the 
posterior surface of the jejunum, which stabilizes and aligns the appropriate. An alternative 
reconstruction uses the EEA stapler .
 
PROXIMAL GASTRECTOMY
An simple midline incision is made in the  abdomen
The left lateral segment of the liver is taken down and retracted, the esophageal hiatus is 
identified, and the soft  tissue around the diaphragmatic hiatus is  incised. The extent of the 
lesion is appreciated rapidly, and on occasion, local invasion into the crura of the diaphragm 
may need crural resection. The retroperitoneal attachments to the diaphragm on the left side 
then are incised, coming down toward the anterior surface of the left adrenal gland. Once the 
esophagus is mobilized, it can be retracted upward and forward, and a decision can be made as 
to the extent of resection required.
For cardiac lesions that are locally extensive, the spleen is mobilized and taken with the 
specimen. In more localized lesions,  the short gastric  vessels are taken close to the splenic 
hilum to enable greater mobilization. On the right side, the right crus is cleared, and all tissue is 
taken back to the celiac axis  origin.  The section then is  carried forward along the anterior 
surface  of  the  celiac  axis  to  identify  the  left  gastric  artery. In  the  majority  of  
PARTIAL GASTRECTOMY
                            CUT SPECIMEN OF    CA  STOMACH
patients, all lymph nodes along the lesser curvature can be dissected readily and reflected back 
toward the proximal gastrectomy with the specimen. Care must be taken not to devascularize 
the lesser curvature. An appropriate distal site on the greater curvature is identified, and the 
stomach is divided with two passages of the GIA-60 or TA stapler. This can be done in an 
oblique fashion so as to create a relative tube of the distal stomach .
SUB TOTAL GASTRECTOMY
 (If  the   proximal  luminal resection  margin   is 5- 6 cm)  .Removal of   80%  of  distal 
stomach     leaving  the  short  gastric  vessels  intact   to   ensure   splenic 
preservation.Reconstruction is  by   either  roux en  y  or  billroth  ІІ   or  polya.
DISTAL GASTRECTOMY:
( Antral growth  with   5cm  marginal  clearance ) .Removal of  less than   80%  of 
stomach   with  reconstruction.
PALLIATIVE   PROCEDURES
(For   advanced gastric cancer  to minimize  bleeding   and gastric out let obstruction)
• Gastrectomy 
• Anterior  gastro jejunostomy
• Laser or argon  beam  tumour  ablation  with laser  recanalization.
• Endoscopic  placement  of  coated  metallic  stents.
COMPLICATIONS  OF SUGERY:
The most devastating complication is anastomatic leak, which occurs in 3% to 21% of 
patients. Dumping syndrome will develop in 10% of patients.early dumping typically occurs 15 
to30 minutes after meal and includes diaphoresis,abdominal cramps, palpitations and watery 
diarrohea. Late dumping is usually associated with hypoglycemia and hyperinsulinemia. The 
management include dietery habits and if refractory, a somatostatin  analog.
Other complications are 
• Bleeding – 0.3-5%
• Pulmonary 3-55%
• Infection  3-22%
• Anastomotic  leak  3-21%
• Cardiac 1-10%
• Renal 1-8%
• Pul. Embolus -1-4%
OUT COME OF SURGERY
The  overall  5  yr  survival  rate  is  10-21  percent  who  undergo  potentially  curative 
resection  has a slightly better prognosis with a 5 year survival rate of 24% to 57%. The 5 year 
survival rate who under go curative resection is 50% .The overall locoregional recurrence rate 
was 38% the median time to death from the time of recurrence was 6 months. 
Neoadjuvant therapy
The advantages  of  Neoadjuvant  chemotherapy is decreased tumour seedling at surgery 
and tumour sensitivity to a chemotherapeutic regimen.drugs used are  etoposide, cis platin, 5-
fluro uracil . The clinical response rate of combination of etoposide ,cisplatin and  5Fu  range 
from  21% - 31%.
Adjuvant chemo therapy
The adjuvant chemotherapy of  5Fu  was   associated with  a  survival  benefit  of  95%.
Post  op External  beam Radiation therapy
The combination of 5Fu with 40gy external beam radiation therapy versus RT alone 
showed improved survival. The three year survival rate for chemo RT were 52% compared to 
surgery only group   40%
Management of Advanced Disease
About 20-30% patients present with stage IV disease. The 5yr survival rate for patients 
with  stage  IV  disease  is  zero.  Because  of  this  low  cure  rate  and  advanced  disease  at 
presentation, palliation is an essential component of gastric cancer Management.
Palliative surgery
Surgery  achieves  good  palliation  less  than  50%of  the  tome.  The  procedure  include 
palliative  Distal gastrectomy with  acceptable mortality  rates. Palliative total gastrectomy & 
esophago gastrectomy should be approached with greater caution because the morbidity from 
these procedures is higher 4%.
Palliative chemotherapy
The Combination regimen included FAMTX(5Fu, doxorubicin, Methotrexate) FEMTX 
(5Fu, epirubucin, Methotrexate) and ELF(etoposide, leucovorin, &5Fu) patients who received 
combination chemotherapy had better survival.
Pallative Radiation therapy:
No large prospective trial has demonstrated a long term benefit  from  radiation  therapy.
Palliation by Endoscopic means include laser recanalisation (or) simple dilation with 
(or) without  stent placement can be used to treat obstruction.
Intraperitoneal Hyperthermic Perfusion
This   procedure  is  a  combination  of  hyperthermia  & Mitomycin  C.  Fujimoto  et  al 
reviewed that  patients  treated with perfusion survived  longer(1 year survival  rate  80% vs 
34%).
CA STOMACH WITH  LIVER SECONDARIES 
OESOPHAGOJEJUNOSTOMY
Immunotherapy
Machara et al reported a combination of  chemotherapy and intraperitoneal  injections of 
OK-432  had  a  long   survival  rate.  Other  immunotherapy’s  are  mycobacterium  derived 
polysaccharides.
Gastric Lymphoma
The Stomach is the most common site of lymphoma in GIT.  The average age of patients 
is 60 years.the most frequent site ofpresentation are pain, weight loss,bleeding and fatigue. 
H.Pylori appears to be a causative agent is the development of gastric lymphoma and MALT 
lymphoma.  Endoscopy detect  the lesion is 80% of cases as sub mucosal infiltration.Other Lab 
test include lactate dehydrogenases  and B2 Micro globulin determination.  The pathological 
type of NHC is  B cell Type & diffuse histiocytic type. Treatment include Acid Suppression 
therapy, Metrogyl and Antibiotic.Anti H. PYLORI treatment is necessary for eradication of H. 
p ylori. External beam irradiation and chemo therapy is offered to those who do not respond to 
an antiobiotic eradication and high risk patients.  Gastric resection is rarely performed for pt. 
with  MALT  lymphomas.surgery  is  necessary  in  some  cases  to  confirm  diagnosis.Surgical 
resection is   curative in patients  with localized disease,  although  half  of  resected patients 
require  chemotherapy.If surgery is performed,an attempt is made to resect the area grossly 
involved with lymphoma but leave grossly  normal stomach intact. Negative margins are not 
necessary for cure. Surgery alone produces survival rate of 82%, where as radiation therapy 
produces  five year survival rate of only 50%. 10- year survival rates  of 80% have been seen in 
patients with Ann Arbor staging of stage ІE  and Stage ІІ .Patient with lymphoma  are initially 
treated  with  chemo  therapy  of  CHOPP   regimen.  Radiation  and  surgery  are  reserved  for 
patients  who do not have a complete response to chemotherapy.
Gastric Carcinoid
Gastric  carcinoid  constitute  only  2%  of  carcinoid  tumors.  gastric  carcinoids  are 
classified into three types .  Type І  carcinoids are associated with type A chronic atrophic 
gastritis,  Type  ІІ   carcinoids are associated with Zollinger-Ellison  syndromewith multiple 
endocrine  neoplasia  syndrome-І,  and  type   ІІІ   are  sporadic  gastric  carcinoids.  Type  І 
carcinoids  are the most common type of gastric carcinoid and are found predominantly in 
women. These patients have typically have elevated plasma gastrin levels and  low gastric acid 
production. Type ІІ  gastric carcinoids are the least common type, accounting for 8% of cases 
with  an  equal  distribution.  Even  they  are  associated  with  Zollingar  Ellison  syndrome  in 
conjunction with MEN- І  they share features with type -1 carcinoids,such as location in the 
fundus, multricentricity, elevated plasma gastrin  level and small size.Type ІІІ  carcinoids , 
which are sporadic carcinoids, represent  23% of cases and are  found predominantly  in men; 
The mean age of patients at diagnosis is 49 years. Patient may complain of histamine producing 
symptoms,  such  as  cutaneous  flushing,bronchospasm,itching  and lacrimation.  The  sporadic 
tumours are  single, solitary ,large and located in the antrum or fundus of stomach. The natural 
course  of type ІІІ  carcinoids is more aggressive with hepatic metastasis  found at diagnosis in 
upto  50% of cases.
           Gastric carcinoids are diagnosed by both biochemical and histologic means. Upper 
gastrointestinal  endoscopy, including endo ultrasound, is also essential to evaluate the number, 
size ,extent  and location of lesions. Extensive gastric biopsy  should be performed in those 
with  suspected  gastric  carcinoids,  checking  for  histologic   chromogranin,  features  of 
dysplasia,mucosal  atrophy,and  the  degree  of  mucosal  invasion.it  appears  that  the  rate  of 
diagnosis correlates with the number of biopsys performed.CT of the abdomen is essential to 
exclude  metastasis to the liver and nodal involvement.
The type of gastric carcinoid  dictates the  nature of treatment  .for patients with either 
type   І or type ІІ  carcinoids and with tumours less than 1 cm or with fewer than three to five 
lesions,  treatment  typically  consists  of  an  endoscopic  polypectomy or  endoscopic  mucosal 
resction.Antrectomy or local excision may be performed in a young patient with an elevated 
gastrin  level  who has recurrent or multifocal disease..  This treatment will  decrese  gastrin 
levels and frequently  leads to  the regression of the tumours. Older patients with many lesions 
may  be  followed  if  the  lesions  are  small.  For  diffuse  or  recurrent  disease,  a  completion 
gastrectomy  may  be  recommended,  depending  on  the  patients  age  and  course  of  the 
disease.Type ІІІ disease should be considered for en bloc resection with  lympadenectomy, 
depending on the tumour size.It appears that five year survival rate  for patients  with type І and 
type ІІ  gastric  carcinoids are between 60% and 75%.in contrast,  the five  year survival   in 
patiets   with type ІІІ  gastric carcinoids  is less than 50%. Follow up in patients with gastric 
carcinoids primarily consists of plasma chromogranin  estimation. Plasma gastrin and urinary 
5-HIAA levels may also be evaluated, although urinary 5-HIAA  levels. 
GASTRO INTESTINAL STROMAL TUMOURS 
GISTs are the most common mesenchymal tumors of the stomach, with the stomach 
being the most common location of these tumors in the gastrointestinal tract (40%), followed by 
the small  intestine (32%). GISTs of the stomach are predominantly found in males,  with a 
median age at diagnosis of 63 years. The presenting features in these patients are varied and 
include bleeding (38%), abdominal pain (11.8%), and rupture (1%); 12% of patients have no 
symptoms. The median size of GISTs of the stomach is 6 cm.
Regardless of the location of  these tumors in the stomach,  R0 resection remains the 
treatment of choice, conferring a 5-year survival of 55%. Several studies have shown that the 
features recommended in the NIH guidelines, tumor size (>5 cm) and mitotic index (>5/50 hpf), 
are associated with a less favorable outcome. Tumor location in the gastroesophageal junction 
or fundus, ulceration, coagulative necrosis, and mucosal invasion were found to be associated 
with  a  poor  outcome  .Antral  tumors,  however,  were  found  to  be  associated  with  a  more 
favorable outcome .Those patients with unresectable or metastatic disease are offered treatment 
with Imatinib (Gleevec, an oral tyrosine kinase inhibitor). They may then be  re-evaluated  for 
potential resection if they demonstrate response to  treatment. 
OBSERVATION
 Cancer stomach is one of the commonest abdominal  malignancy in our region.
 The incidence of distal growth continues to be increasing in our region.
 The incidence of CA stomach in distal part  usually present with age above 50yrs.
 Cigarrete smoking showed increase in proximal cancers when compared   distal cancers.
 The association between Blood group A and Carcinoma Stomach correlate with the study of 
AIRD ET AL.
 Endoscopy and Biopsy have a high sensitivity in picking up all subsite growths. 
 The intestinal type and in association with distal growth  have a favourable prognosis in 
operable cases.
 Stage 4 disease is common in proximal cancers which shows poorer prognosis  in over all 
survival
 Gastrectomy with its acceptable morbidity  is associated with good quality of life, whenever 
the tumour is operable
 Total Gastrectomy carries a high morbidity and mortality when compared to subtotal and 
partial Gastrectomy
CONCLUSION
 The causes of Distal stomach cancer continues to be commoner than    proximal  cancers 
among  Indians.
 The Etiology of carcinoma stomach tends to be  different etiology  in both proximal and 
distal cancers.
 H.Pylori has a 45 .5% association of ca stomach and it is mostly associated with distal 
growths.
 Endoscopy has a high sensitivity in detecting all subsite growths but least sensitivity in 
detecting early cancers. 
 Most cases  present with stage 4 disease which  shows   absence of screening of this 
disease.
 Curative subtotal and distal gastrectomy is associated with good quality of life whenever 
the tumour is operable.
 Mortality is due to increase in duration of  surgery  and  associated   co-marbid illness 
and   anastomotic  leak.
S. Name Rel IPNo. Age/ SE SM AL Diet Subsite Pain Vom/ Mass L/N L/A
MASTER CHART
No Sex DYSPHAGIA
1 Asokan H 17640 65/M 800 √ √ M Antrum √ √ √
2 Pattanaasari H 47730 60/M 800 M Antrum √ √ √
3 Gurusamy H 30628 50/M 800 M Antrum √ √
4 Rajammal H 28355 50/F 800 M Antrum √ √ √
5 Kalliammal H 33605 55/F 800 M Antrum √ √ √ √
6 Pillaikani H 21600 54/M 800 √ M Antrum
7 Mayillappan H 14828 64/M 800 √ M Antrum √ √ √
8 Ayyadurai H 2733 45/M 800 √ √ M Antrum √ √ √
9 Palaniappan H 281395 62/M 800 √ √ M Antrum √ √ √ √
10 Muppidathi H 35131 55/M 800 M Antrum √ √
11 Muhtukutti H 19729 49/M 800 M Body(LC) √ √ √ √
12 Murugan H 26428 55/M 800 √ √ M Antrum √ √ √ √ √
13 Babu H 36204 67/M 800 √ M Antrum √ √ √
14 Muthiahdevar H 35208 65/M 800 √ M Body(GC) √
15 Thiraviampillai H 5705 70/M 800 M Antrum √ √ √ √
16 Ravikumar H 37841 24/M 800 M Antrum √ √
17 Mohammed m 36686 47/m 800 √ √ fat antrum √ √
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1. √ A+ve Antral wall  thickening Antral GrowthGoo Adeno ca
Antral Growth
LN+ Fixed to Panreas
2. √ AB+ve Antral wall  thickening AntralGrowth Goo Adeno ca
Antral Growth Liver 
2° Ascites
3. √ O+ve (N) AntralGrowth Adenoca
Antral Growth
Mesentric
deposits
4. √ 
(E)
√
B+Ve (N) (N) - Growth Antrum
5. √
(RHC)
√
AB+ve Antralwall thickening2° Liver Ascites
Antral
Growth Adeno ca
Growth Antral
2° Liver
Acites
6. √ √
(E)
√
AB+ve
Antralwall
thickening AntralGrowth Adeno ca
Antral Growth
LN6
7. √ √ B +ve
Antralwall
thickening
para ao rtic LN
Antral
Growth
Antral Growth
LN fixed to pancreas, 
TC, PA, PD,Ascites
8. √ B+ve Antral wall thickening Antral growth Adeno carcinoma
Antral Growth
LN infiltration to 
pancreas
9. √ √ B+ve Dilated stomach Pre pyloriculcer Adeno carcinoma
Antral Growth
Perigastric
LN
10. √ B+ve Duodenal thickening Antral Growth & Goo Adeno carcinoma Antral Growth LN
11 √ B +ve Antral wall thickening GOO Adeno carcinoma
Growth LC
Pancreas infiltration, 
LN
12
RHC √ 3cm B +ve
Antral wall thickening,
PALN,2°Liver
Antral Growth & 
Goo
Growth LC
Pancreas infiltration, 
TC,LN,ASCITES
13
E √ O+VE Antral wall thickening Antral Growth
Antral Growth
Mesentric
deposits
14
E
√
A +ve Growth BodyAscites 2° liver Growth Body Adeno carcinoma +
Growth Body
Ascites 2
15
E
√
O +ve Antral wall thickening,PALN, Pyloric Antrum Adeno carcinoma
Growth Antrum fixed 
to pancreas, TC,LN 
Mesentric
deposits
16. √ LHC A +ve N Antral Growth Poorly differentiatedAdeno carcinoma
Growth Antrum fixed 
to pancreas, TC,LN
17
18 Natarajan H 39830 58/M 800 √ √ M CARDIA √ Dysph
agia
√
19 Samuvel C 35767 50/M 800 √ √ M Antrum √ √
20 Mariappan H 14578 64/M 800 √ √ M Antrum √
21 Muthiah H 23988 57/M 800 √ √ M Antrum √ √ √
22 Shanmugavel H 27093 61/M 800 √ M Antrum √ √ √
23 Muthiahdevar H 26818 61/M 800 √ √ M Antrum √
24 Soundarrajan H 27778 40/M 800 M Antrum √ √
25 Balaiah H 21981 55/M 800 √ M Antrum √ √ √
26 Vellammal H 3988 55/F 800 M Antrum √ √ √ √
27 Velu H 15037 68/M 800 M Antrum √ √ √ √
28 Ramakrishnan H 51154 60/M 800 M Antrum √ √ √
29 Kanagaraj H 18898 45/M 800 √ √ M Antrum √ √ √ √
30 Velkani C 18974 52/F 800 M Body(GC)
LINITIS
√ √ √ √
31 Seenidurai H 20148 50/M 800 √ √ M Body
LINITIS
√ √ √ √
32 Muthupandi H 24804 65/M 800 √ M Antrum √ √ √
33 Lakshmi H 30615 50/F 800 M Antrum √ √ √
34 Narayanan H 21064 60/M 800 M Antrum √ √ √
35 Ganapathi H 14009 50/M 800 √ M Antrum √ √ √
36 Alphonse C 13893 50/M 800 M Antrum √ √ √
18 √ √
O+ve Mass body of stomach BodyLC
Growth Antrum fixed 
to pancreas, TC,LN 
Mesentric
deposits
19 √ √ O+ve Ectopic KidneyGB Calculus
Growth
Antrum
Growth Antrum fixed 
to pancreas, TC
20 √ B +ve DistendedStomach
Growth
Antrum
Growth antrum
LN
21 √ √ O+ve Antral wall thickening GrowthAntrum
Growth Antrum fixed 
to pancreas,coeliac
22 √
E
√
O +Ve Antral  GrowthPALN
Growth
Antrum
Poorly differentiated
Adeno carcinoma
Growth Antrum fixed 
to pancreas,LN
23
E √ O+ve
Antral wall thickening
2°Liver GrowthAntrum Adeno carcinoma
Growth
Antrum2
LN,Ascites
24 √ A+ve N AntralGrowth
Growth Antrum 
mesenteric
LN, Ascites
25
E
4c
m
√ O+ve
Antral wall thickening
2°Liver
Ascites
Antral
Growth
GOO
Growth Antrum, 2
Ascites
26 √ E √ A+ve Antral wall thickening
Antral
Growth
GOO +
Growth Antrum Fixed 
to TM
27 √ E √ B+ve DuodenalPathology
Antral
Growth
Growth Antrum gross 
Ascites
fixed
28 E √ B+ve
Antral
Wall
thickening
Antral
growth
Growth Antrum
LN Al to TC
29
LHC √ AB+ve Antral growth LN ascites + Anthralgrowth
Poorlydiffer
Adeno carcinoma
Growth
Antrum 2
LN+
30 √
LHC
√
AB+ve ascites
Anthral
Growth,
Linnitus,
plastica
Poorlydiffer
Adeno carcinoma √
Contracted thickened
Stomach LNO
Ovary  infil.
31 √ E(RHC) √ A +ve Massepigastrium
Linitis
Plastica
Adeno ca √ Antral GrowthBody to Antrum
32 √ E
4 
cm
B+ve Antral Wallthickening
Antral
Growth
Mucinous
Adeno ca Antral Pyloric Growth
33 E AB+ve Antral WallThickening,2° liver
Antral
Growth
2°Liver
Antral Growth PALN
34 √ E √ AB+ve
Antral
Wall
LN, Ascites +
Antral
Growth
Antral Growth
to Body fixed to 
pancreas, TC,LN
35 √ E √ A +ve Ascites GOOMRD
Antral
Growth Adeno ca
Growth Antrum
Ascites
36 √
O+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth
37 Shamugathai H 37868 58/F 800 M Antrum √ √ √
38 Sudalai H 39760 74/M 800 √ √ M Antrum √ √ √
39 Arunachalam H 3095 60/M 800 M Antrum √ √ √
40 Vedhamanikam H 49220 55/M 800 M Antrum √ √ √
41 Thirumaki H 16078 63/M 800 √ √ M Antrum √ √
42 Ramalakshmi H 22240 47/M 800 M Antrum √ √ √ √
43 Dharmar H 36087 58/M 800 √ √ M Antrum √ √ √ √
44 Thirumalai H 16078 63/M 800 √ √ M Antrum √ √ √ √
45 Ramaih H 27873 40/M 800 √ M Antrum √ √
46 Grace C 18080 45/F 800 M Antrum √ √
47 Andidevar H 31637 60/M 800 √ M Antrum √ √ √
48 Narasiman H 9276 55/M 800 √ M Antrum √ √ √
49 Nagalingam H 25936 54/M 800 √ M Antrum √ √ √ √
50 Rawathy H 28113 50/F 800 M Antrum √ √
51 Ramachandran H 52332 40/M 800 M Antrum √ √ √
52 Muthammal H 33603 57/M 800 M Antrum √ √ √
53 Ayyanu H 50078 65/M 800 √ √ M Antrum √ √ √ √
54 Msooth M 31106 60/M 800 √ M Body(GC) √ √ √
55 Subbiah H 36270 75/M 800 √ √ M Antrum √
37 √
LHC O+ve 2° liver AntralGrowth
Mod. diff
Adeno ca
Antral Growth
2° liver Fixed to T4 
pancreas
38 √ √ O+ve
Antral
Wall
Thickening,Ascites
Antral
Growth
Antral Growth
Fixed to 2
Ascites
39
E √ O+ve
Antral
Wall
Thickening
Antral
Growth
Goo
Adeno ca Antral GrowthFixed Post LN
40 √
O+ve
Antral
Wall
Thickening
Antral
Growth Adeno ca Antral Growth
41 √ E √
B+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth 
Perigentric LN
42 √ E √
B+ve
Antral
Wall
Thickening
Antral
Growth Antral Growth CN
43
E O+ve
Antral
Wall
Thickening
Antral Growth PH
44
E √ A+ve
Antral
Wall
Thickening
Antral
Growth
Antral Growth Ascites 
mesenteric
LN
45 √ B+ve N AntralGrowth Adeno ca
Antral Growth
46 √ B+ve N AntralGrowth Adeno ca Antral Growth LN
47 ERHC √ A+ve AntralThickening ascites +
Antral Adeno ca Antral Growth LN Ascites
48
E
4 
cm
AB+ve AntralThickening Liver Ascites Antrum
Poorly Diff
Adeno ca
Antral Growth 2
Liver ascites
49
E
3 
cm
B+ve AntralThickening Antrum
Antral Growth 2
Liver LN + PD+
50 √ E √
3c
m
AB+ve AntralThickening 2° Liver Antrum Adeno ca
Antral Growth LN 
2°Liver with 2
Pancreas
51 √E O+ve AntralThickening Antral Growth Antral Growth 2
52
√E √ AB+ve 2° Liver ascites Antrum Body Antral ascites fixed to pancreas TC
53 √ √ B+ve AntralThickening Antral Growth Antrum 2
54 √ E E AB+ve AntrumThickening 2˚liver N
Antrum  Body 2
LC
55 √ O+ve Ascites R+PlEffu……….. N
Antrum 2
LN
56 Muthah ayyar H 31878 67/M 800 √ V Antrum √ √ √
57 Durairaj H 25389 56/M 800 √ √ M Antrum √ √ √
58 Muthiah H 218324 84/M 800 M Antrum √ √ √ √ √
59 Sudalai H 14342 64/M 800 √ M Antrum √ √ √ √
60 Sankaranaryan H 38225 35/M 800 √ √ M Antrum √ √ √ √
61 Yesuvadian C 3550 65/M 800 √ √ M Antrum √ √ √ √
62 Ramasubhu H 20315 55/M 800 √ √ M Antrum √ √
63 Subramanian H 19426 70/M 800 √ √ M Antrum √ √ √
64 Muthusamy H 91484 45/M 800 √ √ M Body(Gc) √ √
65 Murugan H 20326 50/M 800 √ √ M Cardia √ Dysph
agia
√ √ √
66 Narayanan H 19252 45/M 800 √ √ M ANTRUM √ √
67 Abraham C 21382 54/M 800 √ √ M AntrUM √ √ √
68 Mahalingam H 24529 38/M 800 √ √ M Antrum √ √
69 Jeyankani H 14206 48/F 800 M Body(LC) √ √ √
70 Rangitham H 22236 46/F 800 M Body(GC) √ √
71 Paramasivan H 20313 60/M 800 √ M Antrum √ √ √
72 Ramasubbu H 4298 43/M 800 √ M OG jn √ Dysph
agia
73 Ganapathy H 40239 72/M 800 M Body(GC) √ √
74 Arumugam H 30803 58/M 800 √ M Antrum √ √ √
56 √ E
2 
cm
O+ve Antrum Thickening 2˚ liver ascites Antral Growth
Antrum Ascites 2
liver post. fixed
57
E
2c
m
√ O+ve AntrumThickening 2˚liver Antral Growth
Antrum Ascites 2
liver
58 √ E
4c
m
√ B+ve Antral2˚liver LN Antral Growth
Antrum 2
Ascites
59
E
3c
m
AB+ve Antrum 2˚LiverLN Antral Growth
Antrum 2
LN Ascites
60 √ B+ve Antralwall thickening Antral Growth
Antrum
LN
61 √ E √ B+ve Antralwall thickening Antral Growth Adeno ca Antral GrowthLN+ Fixed to Panreas
62 E √ O+ve Antralwall thickening AntralGrowth Adeno ca
Antral Growth  LN 
mesenteric deposits
63 √ E E √ B+ve Antralwall thickening ln +
Antral
Growth Antrum LNAscites
64 LHC
AB+Ve (N) Growth BodyGC
FNAC LN
Adeno ca Growth Body
65 √ E A+ve (N) Fundal growth Growth Fundus
66 √ E √ B+ve Antral growth AntralGrowth
Adeno ca Antrum   to 5m below
67 √ √ O+ve
Antral
thickening AntralGrowth
Adeno ca Antral LN 2
68 √ AB+ve Normal Body LC Adeno  ca BodyLC
69 E A +ve Growth BodyLC Adeno  ca
Body LC
LN
70 O+ve Antral wall thickening BodyLC
Body LN
71 E √ A+ve Antral wall thickening AntralGrowth Adeno ca _ Antrum PD, MD
72
E AB+ve N Cardiac Growth Adeno ca Cardia
73 E A+ve Antral wall thickening BodyGC Adeno ca + Body GC Ascites +
74 E A+ve Antral wall thickening Antrum Adeno ca Antral Growth fixed to Pancreas, LN ascites
75 Murugan H 25549 49/M 800 √ M Body(GC) √
76 Lakshmi H 99969 47/F 800 M Antrum √ √ √
77 Ganapathy H 32797 62/M 800 M Antrum √ √ √
78 Subbiah H 23465 65/M 800 √ √ M Antrum √ √ √ √
79 Shanmugam C 26217 60/F 800 M Linitis 
plastica
√ √
80 Kandiahdevar H 49520 60/M 800 √ M Antrum √ √
81 Mani H 17314 60/M 800 √ M Antrum √ √ √
82 Ganapathy H 31909 66/M 800 √ M Antrum √ √ √
83 Narasingamal H 21870 30/F 800 M Antrum √ √
84 Mani H 17414 60/M 800 √ √ M Antrum √ √ √ √ √
85 Sappani H 49413 43/M 800 √ M Body(GC) √
86 Subramani H 17575 55/M 800 √ √ M Antrum √ √ √
87 Mariammal H 39539 67/F 800 M Body(GC) √ √ √ √
88 Ganapathy H 60604 67/M 800 √ √ M Antrum √ √ √ √
89 Manivelraj H 5434 40/M 800 √ √ M Antrum √ √ √ √ √
90 Valliammal H 57286 65/F 800 √ √ M OG JN √ Dysph
agia
√
91 Thriumalai H 34679 67/M 800 √ √ M Antrum √ √
92 Arjunan H 37623 50/M 800 √ M Antrum √ √ √
93 Thayammal H 33860 55/F 800 M CARDIA Dysph
agia
√
75 E
O+ve Antral wall thickening BodyGC Adeno ca
Body
GC
LN
76 √ B+ve Antral wall thickening Antrum Antrum
77 E O+Ve Antral wall thickening Antrum Poorly differentiated Adeno ca
Antrum
TC
78
E
2 
cm
A+ve Antral wall thickening, 2˚ Liver PALN
Antral
Growth Antrum 2
79 E √ O+Ve Antral wall thickening, 2˚ Liver Adeno ca 2˚ Liver Ascites
80 E √ A+ve Antral wall thickening, 2˚ Liver
Antral
Growth Adeno ca Antrum 2
81 √ √ O+ve AntralThickening ascites
Antral
Growth Antrum Ascites +F
82 √ E B+ve Antral wall thickening AntralGrowth
Adeno ca
Well differentiated Antrum LN
83 √ B+ve Antral wall thickening AntralGrowth Antrum LN
84 √ E √
4c
m
√ A+ve Antral wall thickening AntralGrowth Antrum +LN,+TC
85 E O+ve N CT BodyGC Body GC LN
86
E √ A+ve N GOO Adeno caWelldifferentiated
Antrum Ascites
PB MC
Roux en y
87 √ √ O+ve Antral wall thickening AntralGrowth Adeno ca
Body 
-----------------------------
88 √ E
2c
m
O+ve Antral wall thickening,2˚ liver
Antral
Growth
89
E
3c
m
√ B+ve Antral wall thickening AntralGrowth
90
E √ √ AB+ve N Body GC
Growth Body Ascites 
+PD +POH Int to 
pancrease
91 √ √ √ √ O+ve Free Fluid LN Antral Growth
Antral
Growth Adeno ca
Liver 2° Antral growth 
TC infiltration
92 √ √ √ √ B+ve Free Fluid LN Antral wall thickening
Antral
Growth Adeno ca
Growth Antrum 
Ascitic fluid Pelvic 
Deposits
93
√
3c
m
B+ve Hepatomegaly IHBR dilatation PH nodes
Growth
Body of stomach Adeno ca
Growth body of 
stomach 2° Liver PH 
nodes
94 Arumugam H 26655 52/M 800 √ √ M Antrum √ √ √
95 Thangaraja H 34538 60/M 800 √ √ M Antrum √ √
96 Muthusamy H 41489 45/M 800 √ M Body(GC) √ √
97 Petchikumar H 49496 73/M 800 √ √ M Antrum √ √
98 Venkatachalam H 49485 52/M 800 √ M OG JN Dysph
agia
√
99 Ganesan H 7903 64/M 800 √ √ M ANTRUM √
100 Pandi H 5161 45/M 800 M Body(GC) √
101 Selvaraj H 6158 57/M 800 √ M Growth 
Cardia
Dysph
agia
102 Syedmohamed M 31863 60/M 800 √ M Pyloric 
growth
√ √ √
103 Paramasivan H 29576 65/M 800 M Antrum √ √ √ √
104 Joseph C 36392 65/M 800 √ M Antrum 
Growth
√ √ √
105 Vairamuthu H 62501 60/M 800 √ √ M Antrum √ √ √
106 Ganesan H 7903 64/M 800 √ M Antrum √ √
107 Krishnan H 39822 65/M 800 √ √ M Antrum √ √ √
108 Abdulrahim M 40853 65/M 800 √ √ M Antrum √ √ √
109 Manivelraj C 51286 40M 800 √ √ M Antrum √ √ √
108 Perumal H 48604 35/m 800 √ √ m antrum √ √
111 Cristopher C 48670 45/M 800 √ M Body(LC) √ √ √
112 Mohamed 
bashir
M 36636 47/M 800 √ √ M Antrum √ √ √
94 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca + Growth antrum LN
95 √ √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Growth antrum LN
96 AB+ve Normal study Elevated  mucosal irregularity Growth antrum
97 √ √ √
2c
m
√ B+ve Ascites hepaticadenopathy AntralGrowth Adeno ca
2° Liver ascites 
Growth antrum 
Pancreas Infiltration
98 √ √ 3cm
√ B+Ve Liver 2° Growth OG jn √
Growth OG jn PH 
nodes
99 √ √ √ A+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN,TC 
infiltration
100 √ O+ve Liver 2° PH nodes GrowthBody of stomach Adeno ca
Growth body of the 
stomach PH nodes
101 √ √ A+ve N Cardiagrowth Signet ring type
Growth cardia 
LN,Omental deposits
102 √ √ √ √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth
103 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth
104 √ √ AB+ve Distended stomach AntralGrowth Antral Growth
105 √ A+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
106
√
Dvt 
Lt 
LL
A+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN TC 
infiltration
107 √ √ B+ve Distended stomach GrowthBody _ Growth body LN OD+
108 √ √ AB+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
109 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
110 √ √ √ O+ve N Body of Stomach Diffuse Thickening PD+OD ascites
111 √ √ √ B+ve N AntralGrowth Spindle cell ca
Growth Body
LN
112 √ √ AB+ve Antral wall thickening AntralGrowth
Antral Growth LN 
Ascites
113 Sermakani H 3927 38/F 800 M pyloric √ √ √ √
114 Ramar H 16634 48/M 800 √ M Antrum √ √ √ √
115 Anandha 
naryanan
H 25798 66/M 800 √ √ M Diffuse √ √ √
116 Thangaraj H 28985 42/M 800 √ √ M Antrum √ √
117 Maharaja H 32200 35/M 800 √ √ M Antrum √
118 Sermadevi H 33087 35/M 800 √ M Antrum √ √ √
119 Ramalingam H 26012 65M 800 √ √ M Antrum √ √ √ √
120 Thayammal H 33860 60/F 800 M Antral 
growth
√ √ √
121 Krishnan H 39822 65/M 800 M Antrum √ √ √ √
122 Abdulrahim M 40853 65/M 800 √ √ M Antrum √ √ √
123 Ganthimathi H 23160 70/F 800 M Antrum √
124 Arumugam H 26615 52/M 800 √ M Antrum √ √ √ √
125 Perumal H 28760 52/M 800 √ M Antrum √ √
126 Murugesan H 31863 62/M 800 √ √ M Antrum √ √ √
127 Ponnusamy H 34769 60/M 800 √ M Antrum √
128 Arjunan H 3762 57/M 800 √ √ M Antrum √
129 Thangalakshmi H 43811 57/F 800 M Antrum √ √ √
130 Sarumathy H 45465 40/F 800 M Antrum √ √ √
131 Murugan H 15161 31/M 800 √ M Antrum √ √ √
132 Krishnavel H 18433 31/F 800 M Antrum √ √ √
113 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
114 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
115 √ √ √ √ O+ve Ascites
Diffuse 
involvement 
stomach
P00rly diffadenoca √ Contracted stomach LN Ascites
116 √ √ B+ve Antral wall thickening AntralGrowth Antral Growth LN
117 √ √ A+ve Antral wall thickening AntralGrowth _ Antral Growth LN
118 √ √ √ B+ve Antral wall thickening AntralGrowth Antral Growth LN
119 √ √ √ O+ve Antral growth Antral Growth LN
120 √ √ AB+ve Antral wall thickening Body and AntralGrowth Growth Body LN
121 √ √ √ O+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
122 √ √ B+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth LN 
Ascites
123 √ √ √ AB+ve Antral wall thickening AntralGrowth Adeno ca
Antral Growth 2° 
Liver Ascites
124 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca + Antral Growth
125 √ √ √ √ √ O+ve Ascites 2° Liver ? Linitis plastica Adeno ca √ Diffuse thickening
126 √ √ A+ve Antral wall thickening AntralGrowth Adeno ca Antral Growth LN
127 √ AB+ve Antral wall thickening AntralGrowth
Antral Growth Ascites 
LN
128 √ B+ve Antral wall thickening Growth Body Adeno ca Growth Body Antrum
129 A+ve Antral wall thickening AntralGrowth Adeno ca + Antral Growth
130 O+ve N AntralGrowth Serosa not involved
131 √ √ √ O+ve Antral wall thickening AntralGrowth Adeno CA Antral Growth LN
132 √ B+ve N AntralGrowth Adeno CA Antral Growth LN
133 Thangathai H 29312 50/F 800 M Body of 
Stomach
√ √
134 Nallamadan H 51675 70/m 8oo M Antral 
growth
√ √
135 Vellammal H 30566 70/F 800 M Body of 
Stomach
√ √ √ √
136 Thangaraja H 34538 60/M 800 √ √ M Growth 
Antrum
√ √ √
137 Selvaraj H 50590 65/m 800 √ √ M Pyloric 
growth
√ √
138 Avudaithai H 34221 45/F 800 M Growth 
Antrum
√ √
139 Nainarammal H 8591 50/F 800 M Growth 
Antrum
√ √
140 Deivakirubai C 25414 35/F 800 M Growth 
Antrum
√ √ √ √
141 Marial c 48067 50/f 800 M antrum √ √ √
142 Lashmanan H 35426 62/f 800 √ √ M ( F) cardia √ Dysph
agia
143 Chandran H 7148 41/F 800 CARDIA √ Dysph
agia
144 Jamilal M 26987 53/F 800 FATTY 
MEAL
Growth
Og jn
Dysph
agia
√ √
145 Parwathy H 27625 45/m 800 M CARDIA Dysph
agia
√
146 Malliga H 38154 38/F 800 M OG JN Dysph
agia
√
147 Shaloni H 28157 55/M 800 wt-69kg OG   jn Dysph
agia
148 Rajagopal H 38788 55/F 800 M DIFFUSE √ √ √
149 Selvaraj H 51535 65/M 800 √ √ M ANTRUM √ √
150 Marammal H 44086 65/F 800 M PYLORIC √ √
133 √ √ √ √ AB+ve Ascites + Growth Body Adeno CA Growth Body Ascites
134 √ √ √ B+ve N AntralGrowth Growth antrum
135 √ √ A+ve N Growth Body Adeno CA Growth Body LN
136 √ √ √ B+ve Antral wall thickening AntralGrowth Adeno CA
Growth Antral Ascites 
Post. INFIL.
137 √ O+ve Antral wall thickening AntralGrowth Antral Growth LN
138 √ √ B+ve Antral wall thickening AntralGrowth Antral Growth
139 √ B+ve Antral wall thickening AntralGrowth Adeno CA Antral Growth
140 √ √ O+ve Antral wall thickening Ascites
Antral
Growth Adeno CA
Antral Growth Ascites 
2° Liver
141 A+ve Antral wall thickening AntralGrowth Adeno CA
Antral Growth Ascites 
2° Liver
142 A+ve N Cardia Growth Adeno CA Cardia Growth
143 AB+ve Ascites Cardia Growth Adeno CA Growth Cardia Liver 2° Ascites
144 B+ve - Growth OG JN Adeno CA Oesophageal infilt.
145 O+ve N Cardia and Fundus
Growth Cardia and 
Fundus
146 O+ve Liver 2° OG JN Adeno CA Growth OG JN Ascites Liver 2°
147 B+ve N OG JN Poorly DiffAdeno CA
Growth OG JN 
Ascites Liver 2°
148 O+ve Ascites Growth Body Poorly DiffAdeno CA Diffuse involvement
149 A+ve Antral Growth AntralGrowth Adeno CA
Growth Antrum Liver 
150 A+ve Antral Growth AntralGrowth
Poorly Diff
Adeno CA
Growth Antrum Liver 
CA STOMACH PROFORMA
  
Name :
Age :
Sex :
Ip no :
DOA :
DOS :
DOD :
Unit :
Complaints
Mass abdomen    : duration
                           Size
                               Site
 
Pain abdomen     : duration 
                               location
                               nature-  colicky / dullaching /others
Jaundice       : duration
                               obstructive/hepatocellular
Vomiting       : nature   food/bile/blood/others 
Fever
H/o dyspepsia
H/o ball roling movements
Abdominal distension
H/o pruritis
bowel habits – constipation/diahorrea/melena/steatorrhea
H/o drug intake
Past history
DM/HT/TB/BA/IHD
H/O previous surgery
H/o jaundice
H/o blood transfusion
Personal history
Diet;  veg/non veg/mixed/ fatty meals/smoked food
smoker / alcoholic
Menstrual history
Treatment history
General examination
Nutrition
Hydration status
Anaemia.
Jaundice.
Pedal edema.
Lymph nodes.
Vitals-PR :   BP :     RR :     TEMP :
SYSTEMIC EXAMINATION:
PER ABDOMEN :
INSPECTION :
Site :
Size :
Shape :
Umbilicus :
Veins/pulsation
Moves with respiration.
PALPATION:
Consistency
Warmth tederness
Guarding/rigidity
Organomegaly
PERCUSSION:
Liver dullness
Over the mass
Free fluid
Shifting dullness
Fluid thrill
AUSCULTATION
Bowel sounds
DRE
OTHER SYSTEMS - CVS/RS/CNS/LOCOMOTOR
CLINICAL DIAGNOSIS
INVESTIGATIONS
HB%
TC
DC 
ESR
URINE - alb/sug /dep
BLOOD - sug/urea/creatinine
SR - electrolytes-na,k
LFT  -    sr.bilurubin
             SGOT/AST
              SGPT/ALT
              Sr.proteins  - alb/glo/total
X RAY CHEST PA VIEW
XRAY ABDOMEN     - supine/ erect
Endoscopy      - upper gi endoscopy
HPE Report
H.PYLORI
OPERATION NOTES
POST OP FOLLOW UP
Day of ryles tube removal
Day of suture removal
Complications
Period of follow up  -  RT/CT
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